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ABSTRACT: A highly efficient and regioselective approach to new polycyclic embelin derivatives through a domino
Knoevenagel condensation/intramolecular hetero Diels−Alder reaction using O-(arylpropynyloxy)-salicylaldehydes in the
presence of ethylenediamine diacetate (EDDA) is reported. This organocatalyzed protocol is compatible toward a wide range of
aryl-substituted alkynyl ethers with electron-donating and electron-withdrawing groups. When other active methylene
compounds were subjected to this domino reaction the corresponding adducts were obtained in high yield.
■ INTRODUCTION
Natural products scaffolds have been well recognized as
“privileged structures” in terms of their ability to be the basis
for successful drugs.1 An assessment of all FDA-approved new
molecular entities (NMEs) reveals that natural products and
their derivatives represent over one-third of all NMEs.2 Such
scaffolds can be used as cores of compound libraries. As a
privileged scaffold, the benzoquinone core is ubiquitous in many
bioactive natural products and pharmaceuticals.3 Understand-
ably, particular emphasis has been put on the development of
methodologies for its synthesis, with an aim to develop facile and
efficient protocols to provide benzoquinone and benzoquinone-
based compound libraries.4
Embelin (1) is a naturally occurring alkyl substituted
hydroxybenzoquinone and a major constituent of the Andean
medicinal plant Oxalis erythrorhiza Gillies ex Hook & Arn,
belonging to the Oxalidaceae family.5
It has been reported that embelin possess antidepressant,6
antitumor,7 anti-inflammatory,8 analgesic,9 antioxidant,10 anti-
diabetic,11 wound healing,12 and antibacterial properties.13 All
these activities make embelin a “promiscuous compound”14 due
specific interactions with multiple targets such as 5-lip-
oxygenase,15 the stress chaperone mortalin,16 XIAPs,17
NFκB,18 STAT-3,19 Akt20 and mTOR,21 and consequently an
interesting scaffold for synthesizing new and more selective
therapeutic agents.
Since that increased molecular complexity in natural products
and diverse compounds, is associated with improved selectivity
and frequency of binding,22 the development of libraries of
complex compounds with balanced physicochemical properties
could led to obtain compounds having efficient binding with
specific biological targets.23 In this sense, the use of domino
reactions is a good synthetic strategy for the construction of
complex polycyclic scaffolds.24
In recent years the domino-Knoevenagel-hetero-Diels−Alder
reaction, developed by Tietze’s group, has emerged as a powerful
process that not only allows the efficient synthesis of complex
compounds but also permits the preparation of highly diverse
molecules, specially pyran and pyrano-fused carbocycles. These
pyran and pyrano-fused ring systems represent important
molecular frameworks, which are found in a wide range of
natural and synthetic bioactive molecules.25
There are numerous examples of the use of unsaturated
aromatic- and aliphatic aldehydes with several 1,3-dicarbonyl
compounds in intramolecular domino Knoevenagel-hetero-
Diels−Alder reaction (DKHDA). However, the use of alkynes
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as dienophiles in DKHDA reactions is limited due to their low
reactivity compared to alkenes.26 In most of cases nonactivated
terminal alkynes have been used. Thus, the pioneer works of
Balalaie et al. reported the use of CuI as an efficient Lewis acid for
activation of various nonactivated alkynes using different organic
solvents,27 inclusive trifluoroethanol.28 In these cases the
formation of an intermediate copper acetylide is postulated
which is consistent with the observation that only terminal
acetylenes participate in the reaction, and end-capped substrates
do not undergo the cycloaddition reaction. Immobilized ZrO2-
nanopowder in the ionic liquid 1-butyl-3-methylimidazolium
nitrate [bmim][NO3] was used as a suitable Lewis-acid for
DKHDA reactions with unactivated terminal alkynes.29 Parmar
et al. reported a solvent-free tetrabutylammonium-hydro-
gensulfate catalyzed DKHDA using 2-(alkynyloxy)-
acetophenones with pyrazolones.30
Most of the examples of DKHDA with nonactivated terminal
alkynes use 1,3-dicarbonyl compounds such as 1,3-indanedio-
ne,27a Meldrum’s acid and dimethyl barbituric acid.31 Some
active methylene compounds such as 4-hydroxy-coumarin,27c
benzoylacetonitrile,27b 1-phenyl-3-methyl pyrazolone,30,32 dihy-
droindole-2-thione, 4-hydroxydithiocoumarin33 have been also
used, but 2-hydroxy-1,4-benzoquinones have never been
employed in this kind of transformation involving alkynes.
To the best of our knowledge, there are not any papers on
intramolecular DKHDA reactions using non terminal alkynes
type O-(arylpropynyloxy)- salicylaldehydes. Due to our interest
in the preparation of bioactive embelin derivatives13a,b,25c and,
since this natural benzoquinone (1) contains a 2-hydroxy-1,4-
quinonic moiety which is a synthetic equivalent to a 1,3-
dicarbonyl compound, this molecule is an adequate substrate for
DKHDA reactions using the mentioned nonterminal alkynes.
Thus, a series of angular polycyclic embelin derivatives with two
points of diversity could be obtained and some compounds result
more selective and efficient than embelin (1) in biological
bioassays.
■ RESULTS AND DISCUSSION
Compounds that contain an aldehyde functionality together with
a suitably placed 3-phenylprop-2-yn-1-oxy moiety are substrates
which have never been studied before in the DKHDA protocol.
These types of compounds were formed from the corresponding
O-propargylated salicylaldehydes and aryl iodides via Sonoga-
shira cross-coupling reactions. The starting O-propargylated
salicylaldehydes (4) were obtained in excellent yields by reaction
of salicylaldehyde derivatives and propargyl bromide using
K2CO3 in dimethylformamide.
34
For the Sonogashira cross-coupling reactions, initially we
selected the reaction conditions published by Kwong et al.35 for
the preparation of terminal-substituted alkynyl ethers. They used
Pd(PPh3)2Cl2 (3 mol %), Cu I (6 mol %), piperidine (2 equiv)
and dry toluene under nitrogen at 30 °C. Using these conditions
in the reaction of propargylated aldehyde 4a and 1-iodo-4-
methoxybenzene (5a), the resulting alkynyl ether (6a) was
obtained in 56% yield. In order to improve this yield we carried
out the reaction using other aprotic and more polar solvents such
as DMSO and DMF but we did not obtain a higher yield (43%
DMSO, 58% DMF), only when THF was used a 86% yield was
achieved. Table 1 summarizes the yields obtained in the
preparation of a variety of aryl-substituted alkynyl ethers with
two points of diversity.
The reaction appeared to be quite general with respect to a
wide variety of functional groups such as -Cl, -Br, -OMe, and
-CO2C2H5 in salicylaldehyde. The best yields were obtained with
iodo-benzenes having electron-withdrawing substituents as 1-
iodo-3-nitrobenzene (entries 6, 13, 20, 27, 34) and 1-iodo-3-
(trifluoromethyl)benzene (entries 7, 14, 21, 28, 35). However,
the steric hindrance of the iodo-benzenes had significant effect
on the reaction, and the yields were decreased for 1-iodo-2-
methoxybenzene (entries 3, 10, 17, 24, 31). Only in one case,
with the bromo-salicylaldehyde derivative (entry 10), together
the formation of the corresponding aryl-substituted alkynyl
ethers (6j, 57%), an alkyne dimer was also obtained in 26% yield.
To optimize the DKHDA reaction conditions, the reaction of
compound 6a and embelin (1) was chosen as a model reaction.
We decided to carry out the reaction using ethylendiamine
diacetate (EDDA, 10 mol %) as an effective organocatalyst for
the initial Knoevenagel condensation. In the first attempt we
investigated if in the absence of other additional catalyst, the
Table 1. Preparation of Aryl-Substituted Alkynyl Ethers (6a−
6ai)
entry R1 R2 product yield (%)
a
1 5-Cl 4-OCH3 6a 86
2 5-Cl 3-OCH3 6b 97
3 5-Cl 2-OCH3 6c 74
4 5-Cl 3-OH 6d 69
5 5-Cl H 6e 98
6 5-Cl 3-NO2 6f 100
7 5-Cl 3-CF3 6g 96
8 5-Br 4-OCH3 6h 85
9 5-Br 3-OCH3 6i 88
10 5-Br 2-OCH3 6j 57
11 5-Br 3-OH 6k 38
12 5-Br H 6l 94
13 5-Br 3-NO2 6m 88
14 5-Br 3-CF3 6n 82
15 H 4-OCH3 6o 64
16 H 3-OCH3 6p 85
17 H 2-OCH3 6q 61
18 H 3-OH 6r 83
19 H H 6s 78
20 H 3-NO2 6t 84
21 H 3-CF3 6u 86
22 4-OCH3 4-OCH3 6v 82
23 4-OCH3 3-OCH3 6w 84
24 4-OCH3 2-OCH3 6x 56
25 4-OCH3 3-OH 6y 61
26 4-OCH3 H 6z 87
27 4-OCH3 3-NO2 6aa 98
28 4-OCH3 3-CF3 6ab 87
29 4-CO2C2H5 4-OCH3 6ac 85
30 4-CO2C2H5 3-OCH3 6ad 97
31 4-CO2C2H5 2-OCH3 6ae 59
32 4-CO2C2H5 3-OH 6af 55
33 4-CO2C2H5 H 6ag 98
34 4-CO2C2H5 3-NO2 6ah 90
35 4-CO2C2H5 3-CF3 6ai 100
aIsolated yield.
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DKHDA adduct could be formed. We were delighted to find that
adduct 7a was obtained in 23% in refluxing ethanol (Table 2,
entry 1). A series of solvents (acetonitrile, toluene, dichloro-
methane, and dichloethane) were investigated (entries 2−5).
Among the solvents tested, dichloroethane provided the best
yield (entry 5).We also carried out the DKHDA reaction without
EDDA (entry 6), and adduct 7a was achieved in low yield (9%).
When the reaction was performed at room temperature
compound 7a was obtained in 47% yield after 24 h (entry 7).
In order to improve the yield, microwave irradiation was also
used, and adduct 7awas obtained in 93% yield in DCE at 120 °C,
for 10 min.
With the optimized protocol in hand, the scope of this domino
process was then assessed through the variation of aryl-
substituted alkynyl ethers 6 (Table 3). Diversely substituted
angular embelin adducts could be prepared in good yields (up to
100%), demonstrating the versatility of this domino process. As a
general trend, the DKHDA reaction is tolerant to a large variety
of aryl-substituted alkynyl ethers with electron-donating and
electron-withdrawing groups. This substituent diversity results
very attractive for the establishment of structure−activity
relationships after biological evaluation.
The reaction can be rationalized via the formation of a
Knoevenagel adduct intermediate, which undergoes an intra-
molecular hetero-Diels−Alder reaction to form 7 (Scheme 1).
The process is regioselective since only the 1,4-benzoquinone
adduct is obtained from the more electron-poor heterodiene.
Two new fused rings next to the benzoquinone core and three σ
bonds (two C−C σ bonds and one C−O σ bond) were formed in
this domino reaction. The regiosubstitution of the corresponding
adducts was confirmed by the two- and three-bond correlations
detected in the HMBC spectrum and also by the 13C NMR
chemical shifts of the quinone carbonyls.4f,13b,25
The introduction of a phenyl group in the alkyne favors the
energy of HOMO of the dienophile and for this reason is not
necessary an additional activation of the triple bond when aryl-
end-capped alkynes are involved. In fact when the reaction of
embelin was carried out with the terminal alkyne derivative 4a (5-
chloro-2-(prop-2-yn-1-yloxy)benzaldehyde) under the same
reaction conditions (10 mol % EDDA, CH2Cl2, MW, 120 °C,
10 min) the formation of the corresponding adduct was not
detected.
In order to see the scope of this protocol regarding the 1,3
dicarbonyl component, we carried out the DKHDA reaction with
the following 1,3-dicarbonyl compounds: cyclohexanedione (8),
dimedone (9) and barbituric acid (10). The active methylene
compounds 4-hydroxy-6-methyl-2H-pyran-2-one (11), 4-hy-
droxycoumarin (12) and 2-hydroxy-1,4-naphthoquinone (13),
which are of interest from a biological point of view, were also
used. The results are summarized in Scheme 2. As we can see all
enolizable symmetric cyclic 1,3-dicarbonyls annulated efficiently
with 5-chloro-2-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde
(6a) by this one-pot domino procedure. With respect to the
compounds 11−13 two different products easy to separate by
chromatography were obtained as a consequence of the
cycloaddition reaction with the two heterodienes present in
the corresponding Knoevenagel adduct intermediate. Thus, from
the reaction with 4-hydroxy-6-methyl-2H-pyran-2-one (11), 4H-
pyran-4-one (17a) and 2H-pyran-2-one (17b) derivatives were
formed in a 1:1 ratio. In a similar way the pyrano[2,3-c]chromone
(18a) and the pyrano[2,3-c]coumarin (18b) were obtained by
using 4-hydroxy-coumarin (12). In this case the compounds
were obtained in a 1:1.5 ratio in favors of the coumarin derivative
formed from the heterodiene intermediate involving the keto
carbonyl group instead of the lactone carbonyl group. Finally
when the DKHDA between 6a and 2-hydroxynaphthoquinone
(13) was carried out, the corresponding 1,4-naphthoquinone
(19a) and 1,2-naphthoquinone (19b) were obtained in a 1.5:1
ratio in favors of the p-naphthoquinone formed from the more
electron-poor heterodiene. The structures of the adducts (14−
19) were unequivocally determined using 1D and 2D NMR
spectroscopy.
■ CONCLUSIONS
In conclusion, we have reported a microwave-assisted intra-
molecular approach for the synthesis of a set of new angular
tetracyclic embelin derivatives. To the best of our knowledge,
these are the first examples of intramolecular DKHDA reaction
usingO-(arylpropynyloxy)-salicylaldehydes. The presence of the
phenyl group is essential to favors the intramolecular cyclo-
addition reaction. Diversely substituted embelin adducts could
be prepared in good yields from a large variety of aryl-substituted
alkynyl ethers with electron-donating and electron-withdrawing
groups. This efficient organocatalyzed protocol was successfully
Table 2. Optimization of the DKHDA Reaction between 1 and 6a
entry conditions yielda (%)
1 10 mol % EDDA, EtOH, reflux, 3 h 23
2 10 mol % EDDA, CH3CN, reflux, 3 h 48
3 10 mol % EDDA, toluene, reflux, 3.5 h 50
4 10 mol % EDDA, DCM, reflux, 5.5 h 66
5 10 mol % EDDA, DCE, reflux, 3.5 h 68
6 DCM, reflux, 12 h 9
7 10 mol % EDDA, DCM, rt, 24 h 47
8 10 mol % EDDA, DCE, MW, 120 °C, 10 min 93
aIsolated yield.
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applied to a variety of active methylene compounds. We expect
that some of the synthesized compounds, with increased
molecular complexity, result more active and selective than our
starting compound, the natural benzoquinone embelin (1). The
corresponding biological assays are in progress.
■ EXPERIMENTAL SECTION
General Experimental Procedures. IR spectra were obtained
using a Fourier Transform Infrared spectrometer. NMR spectra were
recorded in CDCl3 or DMSO at 500 or 600 MHz for
1H NMR and 125
or 150 MHz for 13C NMR. Chemical shifts are given in (δ) parts per
million and coupling constants (J) in hertz (Hz). 1H and 13C spectra
Table 3. Synthesis of Novel Tetracyclic Embelin Adducts
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were referenced using the solvent signal as internal standard. Melting
points were taken on a capillary melting point apparatus and are
uncorrected. Microwave reactions were conducted in sealed glass vessels
(capacity 5 mL) using a CEM Discover microwave reactor. HREIMS
were recorded using a high-resolution magnetic trisector (EBE) mass
analyzer. Analytical thin-layer chromatography plates used were
Polygram-Sil G/UV254. Preparative thin-layer chromatography was
carried out with Analtech silica gel GF plates (20 × 20 cm, 1000
Microns) using appropriate mixtures of ethyl acetate and hexanes. All
solvents and reagents were purified by standard techniques reported36
or used as supplied from commercial sources. All compounds were
named using the ACD40 Name-Pro program, which is based on IUPAC
rules. The embelin (1) used in the reactions was obtained from Oxalis
erythrorhiza Gillies ex Hook & Arn following the procedure described in
ref 5.
General Procedure for the Synthesis of O-Propargylated
Salicylaldehydes (4a−4e). To a solution of the corresponding
salicylaldehyde (1.0 mmol) in DMF (5 mL) was added anhydrous
K2CO3 (152.7 mg, 1.1 mmol) followed by propargyl bromide (0.13 mL,
1.1 mmol). The reaction mixture was stirred at room temperature until
disappearance of the starting salicylaldehyde. Ice water (100 mL) was
then added and the product was quantitatively obtained by filtration.
5-Chloro-2-(prop-2-yn-1-yloxy)benzaldehyde (4a). Following the
general procedure, to a solution of 0.5 g (3.2 mmol) of 5-
chlorosalicylaldehyde and 0.49 g (3.5 mmol) of K2CO3 in dry DMF
(5 mL), 0.4 mL (3.5 mmol) of propargyl bromide was added to obtain
the propargylated salicylaldehyde 4a34a in a quantitative yield. 1H NMR
(500 MHz, CDCl3) δ 2.58 (1H, t, J = 2.3 Hz), 4.83 (2H, d, J = 2.3 Hz),
7.09 (1H, d, J = 8.9 Hz), 7.51 (1H, dd, J = 2.7, 8.9 Hz), 7.81 (1H, d, J =
2.7 Hz, 1H), 10.40 (s, 1H); 13CNMR (125MHz, CDCl3) δ 56.7 (CH2),
76.9 (CH), 77.0 (C), 114.9 (CH), 126.4 (C), 127.5 (C), 128.2 (CH),
135.2 (CH), 158.1 (C), 188.2 (CH).
5-Bromo-2-(prop-2-yn-1-yloxy)benzaldehyde (4b). Following the
general procedure, to a solution of 0.5 g (2.5 mmol) of 5-
bromosalicylaldehyde and 0.38 g (2.7 mmol) of K2CO3 in dry DMF
(5 mL), 0.31 mL (2.7 mmol) of propargyl bromide was added to obtain
the propargylated salicylaldehyde 4b34a in a quantitative yield. 1H NMR
(500 MHz, CDCl3) δ 2.59 (1H, t, J = 2.4 Hz), 4.83 (2H, d, J = 2.4 Hz,
2H), 7.09 (d, J = 8.8 Hz, 1H), 7.51 (dd, J = 2.8, 8.9 Hz, 1H), 7.81 (d, J =
2.7 Hz, 1H), 10.41 (s, 1H); 13CNMR (125MHz, CDCl3) δ 55.8 (CH2),
76.9 (CH), 77.2 (C), 115.0 (CH), 126.5 (C), 127.7 (C), 128.1 (CH),
135.2 (CH), 158.1 (C), 188.2 (CH).
2-(Prop-2-yn-1-yloxy)benzaldehyde (4c). Following the general
procedure, to a solution of 0.5 g (4.1 mmol) of salicylaldehyde and 0.62 g
(4.5 mmol) of K2CO3 in dry DMF (5 mL), 0.5 mL (4.5 mmol) of
propargyl bromide was added to obtain the propargylated salicylalde-
hyde 4c34a in a quantitative yield.1H NMR (500 MHz, CDCl3) δ 2.57
(1H, t, J = 2.2 Hz), 4.83 (2H, t, J = 2.4 Hz), 7.09 (1H, td, J = 2.9, 7.7 Hz),
7.12 (dd, J = 1.7, 8.4 Hz, 1H), 7.57 (m, 1H), 7.86 (ddd, J = 1.7, 3.4, 7.6
Hz, 1H), 10.49 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 56.4 (CH2),
Scheme 1. Plausible Formation of Compounds 7
Scheme 2. Scope of the Reaction Regarding 1,3-Dicarbonyl Compounds
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76.5 (CH), 77.7 (C), 113.2 (CH), 121.7 (CH), 125.6 (C), 128.6 (CH),
135.7 (CH), 159.8 (C), 189.5 (CH).
4-Methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde (4d). Following
the general procedure, to a solution of 0.50 g (3.2 mmol) of 4-
methoxysalicylaldehyde and 0.49 g (3.5 mmol) of K2CO3 in dry DMF (5
mL), 0.4 mL (3.5 mmol) of propargyl bromide was added to obtain the
propargylated salicylaldehyde (4d)34b in a quantitative yield. 1H NMR
(500MHz, CDCl3) δ 2.58 (1H, t, J = 2.4 Hz), 3.88 (3H, s), 4.80 (2H, d, J
= 2.4 Hz), 6.60 (m, 2H), 7.84 (1H, d, J = 9.1 Hz, 1H), 10.30 (1H, s); 13C
NMR (125 MHz, CDCl3) δ 55.7 (CH3), 55.4 (CH2), 76.6 (CH), 77.6
(C), 99.5 (CH), 106.8 (CH), 119.6 (C), 130.7 (CH), 161.5 (C), 165.9
(C), 188.1 (CH).
Ethyl-4-formyl-3-(prop-2-yn-1-yloxy)benzoate (4e). Following the
general procedure, to a solution of 0.30 g (1.5 mmol) of 4-formyl-3-
hydroxybenzoate and 0.24 g (1.7 mmol) of K2CO3 in dry DMF (5 mL),
was added 0.15 mL (1.7 mmol) of propargyl bromide to obtain the
propargylated salicylaldehyde 4e in a quantitative yield.34b 1H NMR
(500 MHz, CDCl3) δ 1.39 (3H, t, J = 7.3 Hz), 2.59 (1H, t, J = 2.4 Hz),
4.37 (2H, q, J = 7.2 Hz), 4.89 (1H, d, J = 2.4 Hz), 7.17 (1H, d, J = 8.7
Hz), 8.25 (2H, dd, J = 2.3, 8.8 Hz, 2H), 8.51 (1H, d, J = 2.3 Hz, 1H),
10.46 (s, 1H); 13C NMR (125MHz, CDCl3) δ 14.3 (CH3), 56.7 (CH2),
61.2 (CH2), 76.9 (CH), 77.0 (C), 113.1 (CH), 124.5 (C), 125.3 (C),
130.6 (CH), 136.8 (CH), 162.6 (C), 165.4 (C), 188.5 (CH).
General Procedure for the Sonogashira Cross-Coupling of
Aryl Iodides with Propargylated Salicylaldehydes. To a mixture
of 50 mg of the propargylated salicylaldehyde, iodobenzene (1.1 equiv),
and piperidine (2.0 equiv) in 1 mL of dry THF under an Ar atmosphere,
Pd(PPh3)2Cl2 (3 mol %) and CuI (6 mol %) were added successively.
The reaction mixture was stirred at 30 °C until complete consumption
of starting salicylaldehyde. Then the solvent was removed under
reduced pressure provided, and the residue was purified by column
chromatography on silica gel (hexane/EtOAc) to afford the phenyl
propargylated salicylaldehyde derivative.
5-Chloro-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde (6a). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde 4a
with 4-iodoanisole (67.2 mg, 0.27 mmol), Pd(PPh3)2Cl2 (5.4 mg, 3 mol
%), CuI (2.9 mg, 6 mol %) and piperidine (51 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 2.5 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 66.9 mg
(86%) of compound 6a as a yellow oil. IR (neat) νmax 2256, 1696, 1632,
1523, 1474, 1432, 1325, 1225, 1202, 1187, 1154, 1122, 1032, 1010, 961,
897, 744, 705, 632 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.81 (s, 3H),
5.03 (s, 2H), 6.84 (d, J = 8.2 Hz, 2H), 7.18 (d, J = 8.6 Hz, 2H), 6.74 (s,
3H), 7.33 (d, J = 8.6 Hz, 2H), 7.52 (dd, J = 2.0, 8.6 Hz, 1H), 7.82 (d, J =
1.8 Hz, 1H), 10.45 (s, 1H); 13CNMR (125MHz, CDCl3) δ 55.3 (CH3),
57.8 (CH2), 81.1 (C), 88.6 (C), 113.7 (C), 114.0 (CH × 2), 115.2 (CH
× 2), 126.4 (C), 127.2 (C), 133.4 (CH × 2), 135.2 (CH), 158.5 (C),
160.2 (C), 188.5 (CH); EIMSm/z 300 (M+, 4), 286 (11), 277 (16), 262
(100), 183 (48), 155 (48); HREIMS 300.0565 (calcd for C17H13O3
35Cl




benzaldehyde (6b). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-iodoanisole (32.2 μL, 0.27 mmol), Pd(PPh3)2Cl2 (5.4 mg, 3 mol
%), CuI (2.9 mg, 6 mol %) and piperidine (51 μL, 0.5 mmol,) in dry
THF (1 mL) under an Ar atmosphere at 30 °C for 2.5 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 75.8 mg
(97%) of compound 6b as a yellow oil. IR (neat) νmax 1670, 1589, 1473,
1400, 1288, 1258, 1223, 1180, 1126, 995, 957, 899, 810, 752, 687, 648
cm−1; 1H NMR (500 MHz, CDCl3) δ 3.79 (s, 3H), 5.04 (s, 2H), 6.90
(ddd, J = 0.5, 2.5, 8.3 Hz, 2H), 6.95 (dd, J = 1.3, 2.4 Hz, 1H), 7.01 (dt, J =
1.1, 7.6 Hz, 1H), 7.17 (d, J = 8.9 Hz, 1H), 7.22 (t, J = 8.1 Hz, 1H), 7.53
(dd, J = 2.7, 8.9 Hz, 1H), 7.82 (d, J = 2.7 Hz, 1H), 10.46 (s, 1H); 13C
NMR (125 MHz, CDCl3) δ 55.7 (CH2), 57.3 (CH3), 82.2 (C), 88.5
(C), 115.3 (CH), 115.6 (CH), 116.7 (CH), 122.6 (C), 124.3 (CH),
126.6 (C), 127.4 (C), 128.1 (CH), 129.5 (CH), 135.2 (CH), 158.4 (C),
159.4 (C), 188.3 (CH); EIMS m/z 300 ([M+], 10), 270 (1), 237 (1),
145 (100), 102 (13); HREIMS 302.0513 (calcd for C17H13O3
37Cl (M+)
302.0524), 300.0540 (calcd. for C17H13O3
35Cl (M+) 300.0553).
5-Chloro-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde (6c). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde
with 2-iodoanisole (35.1 μL, 0.27 mmol), Pd(PPh3)2Cl2 (5.4 mg, 3 mol
%), CuI (2.9 mg, 6mol %) and piperidine (51 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 57.6 mg
(74%) of compound 6c. IR (neat) νmax 2222, 1678, 1593, 1477, 1438,
1396, 1265, 1223, 1184, 1126, 1045, 1003, 960, 895, 810, 744, 706, 644
cm−1; 1HNMR (500MHz, CDCl3) δ 3.85 (s, 3H), 5.09 (s, 2H), 6.87 (d,
J = 8.5 Hz, 1H), 6.90 (td, J = 0.9, 7.5 Hz, 1H), 7.24 (d, J = 8.9 Hz, 1H),
7.32 (m, 1H), 7.36 (dd, J = 1.6, 7.5 Hz, 1H), 7.52 (dd, J = 2.9, 8.9 Hz,
1H), 7.82 (d, J = 2.7 Hz, 1H), 10.46 (s, 1H); 13C NMR (125 MHz,
CDCl3) δ 55.8 (CH2), 58.1 (CH2), 85.1 (C), 86.4 (C), 110.7 (CH),
110.8 (C), 115.6 (CH), 120.5 (CH), 126.6 (C), 127.2 (C), 127.9 (CH),
130.6 (CH), 133.7 (CH), 135.1 (CH), 158.6 (C), 160.3 (C), 188.5
(CH); EIMSm/z 300 (M+, 4), 281 (4), 262 (3), 182 (2), 145 (100), 115
(39); HREIMS 302.0540 (calcd for C17H13O3
37Cl (M+) 302.0524),
300.0537 (calcd. for C17H13O3
35Cl (M+) 300.0553).
5-Chloro-2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl )oxy)-
benzaldehyde (6d). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-iodophenol (59.4 mg, 0.27 mmol), Pd(PPh3)2Cl2 (5.4 mg, 3 mol
%), CuI (2.9 mg, 6mol %) and piperidine (51 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 2.5 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 51.4 mg
(69%) of compound 6d. IR (neat) νmax 1674, 1577, 1439, 1412, 1373,
1292, 1269, 1199, 1126, 1022, 987, 894, 814, 783, 744, 687 cm−1; 1H
NMR (500 MHz, CDCl3) δ 5.02 (s, 2H), 6.85 (dd, J = 2.0, 8.1 Hz, 1H),
6.90 (dd, J = 1.4, 2.3 Hz, 1H), 7.08 (dt, J = 1.3, 7.7 Hz, 1H), 7.16 (m,
2H), 7.52 (dd, J = 2.7, 8.8 Hz, 1H), 7.81 (d, J = 2.6 Hz, 1H), 10.43 (s,
1H); 13C NMR (125 MHz, CDCl3) δ 57.8 (CH2), 82.3 (C), 88.3 (C),
115.4 (CH), 116.7 (CH), 118.5 (CH), 122.7 (C), 124.2 (CH), 126.4
(C), 127.4 (C), 128.1 (CH), 129.7 (CH), 135.4 (CH), 155.5 (C), 158.5
(C), 188.9 (CH); EIMS m/z 286 (M+, 13), 262 (11), 219 (60), 183
(10), 131 (100); HREIMS 288.0356 (calcd. for C16H11O3
37Cl (M+)
288.0367), 286.0387 (calcd. for C16H11O3
35Cl (M+) 286.0397).
5-Chloro-2-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde (6e). Fol-
lowing the general procedure, the treatment of 50 mg (0.26 mmol) of 5-
chloro-2-(prop-2-yn-1-yloxy)benzaldehyde with iodobenzene (35.5 μL,
0.27 mmol), Pd(PPh3)2Cl2 (5.4 mg, 3 mol %), CuI (2.9 mg, 6 mol %)
and piperidine (51 μL, 0.5 mmol) in dry THF (1 mL) under an Ar
atmosphere at 30 °C for 3 h, followed by evaporation of the solvent
under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 69.0 mg (98%) of
compound 6e37 as a yellow oil. IR (neat) νmax 1678, 1597, 1574,
1477, 1415, 1377, 1272, 1238, 1207, 1173, 1123, 1049, 995, 895, 810,
779, 709, 687, 667 cm−1; 1H NMR (500 MHz, CDCl3) δ 5.04 (s, 2H),
7.17 (d, J = 8.8 Hz, 1H), 7.32 (m, 3H), 7.41 (m, 2H), 7.52 (dd, J = 2,8,
8.8 Hz, 1H), 7.82 (d, J = 2.7 Hz, 1H), 10.45 (s, 1H); 13C NMR (125
MHz, CDCl3) δ 57.3 (CH2), 82.4 (C), 88.6 (C), 115.3 (CH), 121.7 (C),
126.6 (C), 127.4 (C), 128.1 (CH), 128.4 (CH × 2), 131.8 (CH × 2),
135.2 (CH), 158.5 (C), 188.3 (CH); EIMS m/z 270 (M+, 16), 240 (2),
207 (2), 154 (3), 115 (100); HREIMS 272.0425 (calcd for
C16H11O2




(6f). Following the general procedure, the treatment of 50 mg (0.26
mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-nitro-
iodobenzene (67.2 mg, 0.27 mmol), Pd(PPh3)2Cl2 (5.4 mg, 3 mol %),
CuI (2.9 mg, 6 mol %) and piperidine (51 μL, 0.5 mmol) in dry THF (1
mL) under an Ar atmosphere at 30 °C for 3 h, followed by evaporation
of the solvent under reduced pressure and purification on silica gel
column chromatography (Hex/EtOAc, 7:3) afforded 82.8 mg (100%)
of compound 6f. IR (neat) νmax 3522, 3398, 3086, 1674, 1589, 1524,
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1477, 1350, 1227, 1169, 1061, 976, 902, 814, 737, 671 cm−1; 1H NMR
(500 MHz, CDCl3) δ 5.07 (s, 2H), 7.14 (d, J = 8.9 Hz, 1H), 7.52 (t, J =
8.0 Hz, 1H), 7.55 (dd, J = 2.7, 8.7 Hz, 1H), 7.72 (dt, J = 1.2, 7.7 Hz, 1H),
7.84 (d, J = 2.7 Hz, 1H), 8.21 (ddd, J = 1.1, 2.3, 8.3 Hz, 1H), 8.28 (t, J =
1.8 Hz, 1H), 10.46 (s, 1H); 13CNMR (125MHz, CDCl3) δ 57.3 (CH2),
85.1 (C), 85.9 (C), 115.0 (CH), 123.5 (C), 123.8 (CH), 126.5 (C),
126.6 (CH), 127.6 (C), 128.3 (C), 129.6 (C), 135.3 (CH), 137.5 (CH),
148.1 (C), 158.2 (C), 188.1 (CH); EIMS m/z 300 (M+, 10), 270 (1),
237 (1), 145 (100), 102 (13); HREIMS 302.0513 (calcd for
C17H13O3




benzaldehyde (6g). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-trifluoromethyl-1-iododbenzene (38.9 μL, 0.27 mmol), Pd-
(PPh3)2Cl2 (5.4 mg, 3mol %), CuI (2.9 mg, 6mol %) and piperidine (51
μL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30 °C for
3 h, followed by evaporation of the solvent under reduced pressure and
purification on silica gel column chromatography (Hex/EtOAc, 7:3)
afforded 84.9 mg (96%) of compound 6g as a oil yellow. IR (neat) νmax
3522, 3398, 3074, 2874, 1682, 1593, 1744, 1331, 1258, 1215, 1161,
1084, 976, 899, 802, 683 cm−1; 1H NMR (500 MHz, CDCl3) δ 5.06 (s,
2H), 7.15 (d, J = 8.9 Hz, 1H), 7.46 (t, J = 7.7 Hz, 1H), 7.54 (dd, J = 2,7,
8.7 Hz, 1H), 7.60 (t, J = 7.3 Hz, 2H), 7.68 (s, 1H), 7.83 (d, J = 2.8 Hz,
1H), 10.45 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 57.4 (CH2), 84.0
(C), 86.9 (C), 115.0 (CH), 122.6 (C), 125.6 (CH, JC−F = 2.7 Hz), 126.5
(C), 127.5 (C), 128.2 (CH × 2), 128.6 (C, JC−F = 3.7 Hz), 129.0 (CH),
131.1 (C, JC−F = 34.1 Hz), 134.9 (CH), 135.2 (CH), 158.2 (C), 188.1
(CH); EIMS m/z 338 (M+, 16), 308 (3), 272 (5), 182 (100); HREIMS
302.0513 (calcd for C17H13O3




benzaldehyde (6h). Following the general procedure, the treatment of
50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde
with 4-iodoanisole (51.6 mg, 0.27 mmol), Pd(PPh3)2Cl2 (4.4 mg, 3 mol
%), CuI (2.5 mg, 6 mol %) and piperidine (42 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 4:1) afforded 58.4 mg
(85%) of compound 6h as a yellow oil. IR (neat) νmax 2218, 2203, 1678,
1597, 1508, 1474, 1400, 1292, 1254, 1238, 1192, 1254, 1238, 1192,
1123, 1029, 1018, 999, 972, 922, 879, 791, 640, 621 cm−1; 1HNMR (500
MHz, CDCl3) δ 3.80 (s, 3H), 5.03 (s, 2H), 6.83 (d, J = 7.8 Hz, 2H), 7.12
(d, J = 9.1 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.65 (dd, J = 2.5, 8.8 Hz,
1H), 7.95 (d, J = 2.5 Hz, 1H), 7.52 (dd, J = 2.0, 8.6 Hz, 1H), 7.82 (d, J =
1.8 Hz, 1H), 10.45 (s, 1H); 13CNMR (125MHz, CDCl3) δ 55.3 (CH3),
57.7 (CH2), 81.1 (C), 88.6 (C), 113.7 (C), 114.0 (CH × 2), 114.4 (C),
115.6 (CH), 126.9 (C), 131.1 (CH), 133.4 (CH × 2), 138.1 (CH),
159.0 (C), 160.2 (C), 188.3 (CH); EIMS m/z 344 (M+, 29), 314 (6),
262 (4), 145 (100), 102 (70); HREIMS 346.0019 (calcd for
C17H13O3




benzaldehyde (6i). Following the general procedure, the treatment of
50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-iodoanisole (26.3 μL, 0.27 mmol), Pd(PPh3)2Cl2 (4.4 mg, 3 mol
%), CuI (2.5 mg, 6 mol %) and piperidine (42 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 4:1) afforded 63.7 mg
(88%) of compound 6i38 as a yellow oil. IR (neat) νmax 1674, 1589, 1477,
1377, 1323, 1269, 1230, 1207, 1180, 1122, 1084, 1041, 1022, 1003, 987,
883, 837, 783, 702, 682, 652 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.78
(s, 3H), 5.03 (s, 2H), 6.90 (ddd, J = 0.8, 2.6, 8.2 Hz, 1H), 6.93 (dd, J =
1.6, 2.5 Hz, 1H), 7.01 (dt, J = 1.2, 7.7 Hz, 1H), 7.11 (d, J = 8.9 Hz, 1H),
7.22 (t, J = 7.9 Hz, 1H), 7.65 (dd, J = 2.6, 8.8 Hz, 1H), 7.96 (d, J = 2.6 Hz,
1H), 10.43 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 55.3 (CH3), 57.6
(CH2), 82.1 (C), 88.5 (C), 114.4 (C), 115.5 (CH), 115.6 (CH), 116.7
(CH), 122.6 (C), 124.3 (CH), 126.8 (C), 129.5 (CH), 131.1 (CH),
138.1 (CH), 158.9 (C), 159.3 (C), 188.2 (CH); EIMS m/z 344 (M+,
14), 314 (2), 262 (2), 145 (100), 102 (30); HREIMS 346.0036 (calcd
for C17H13O3




benzaldehyde (6j). Following the general procedure, treatment of 50
mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde with
2-methoxy-1-iodobenzene (28.7 μL, 0.22 mmol), Pd(PPh3)2Cl2 (3%
mol, 4.4 mg), CuI (6% mol, 2.5 mg) and piperidine (2 eq 0.5 mmol, 42
μL) in dry THF (1 mL) under an Ar atmosphere at 30 °C for 2.5 h,
followed by evaporation of the solvent under reduced pressure and
purification on silica gel column chromatography (Hex/AcOEt, 7:3),
afforded the corresponding product 6j (50.7 mg, 70%) together the
alkyne dimer 6j′ (13.3 mg, 25%).
6j: IR (neat) νmax 3526, 3402, 2874, 2223, 1686, 1589, 1477, 1385,
1265, 1223, 1061, 1007, 957, 891, 810, 744, 648, 633 cm−1;1H NMR
(500MHz, CDCl3) δ 3.86 (s, 3H), 5.09 (s, 2H), 6.87 (d, J = 8.3 Hz, 1H),
6.90 (td, J = 1.2, 7.8 Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.32 (ddd, J = 1.7,
7.9, 8.3 Hz), 7.36 (dd, J = 1.7, 7.6 Hz, 1H), 7.66 (dd, J = 2.6, 8.9 Hz, 1H),
7.96 (d, J = 2.7 Hz, 1H), 10.44 (s, 1H); 13C NMR (125 MHz, CDCl3) δ
55.8 (CH3), 58.0 (CH2), 85.1 (C), 86.4 (C), 110.7 (CH), 110.8 (C),
114.4 (C), 116.0 (CH), 120.5 (CH), 126.9 (C), 130.6 (CH), 131.0
(CH), 133.7 (CH), 138.0 (CH), 159.0 (C), 160.3 (C), 188.4 (CH);
EIMS m/z 345 ((M+1)+, 3), 328 (2), 262 (30), 183 (14), 145 (100);




6j′: IR (neat) νmax 3522, 3398, 1620, 1473, 1396, 1061, 972, 852, 806,
667 cm−1; 1H NMR (500 MHz, CDCl3) δ 4.90 (s, 2H), 6.97 (d, J = 8.7
Hz, 1H), 7.66 (dd, J = 2.6, 8.8 Hz, 1H), 7.96 (d, J = 2.6 Hz, 1H), 10.37 (s,
1H); 13C NMR (125 MHz, CDCl3) δ 57.0 (CH2), 71.9 (C), 73.8 (C),
115.0 (C), 115.1 (CH), 126.8 (C), 131.4 (CH), 138.2 (CH), 158.3 (C),
187.8 (CH); ESI(+)-MS m/z 498 ((M+Na)+, 100), 449 (52); HR-
ESIMS 496.9000 (calcd. for C20H12O4
79Br2Na 496.8994), 498.8980
(calcd. for C20H12O4




benzaldehyde (6k). Following the general procedure, the treatment of
50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-iodophenol (48.5 mg, 0.22 mmol), Pd(PPh3)2Cl2 (4.4 mg, 3 mol
%), CuI (2.5 mg, 6mol %) and piperidine (42 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 3:7), afforded 26.7 mg
(38%) of compound 6k as a yellow oil. IR (neat) νmax 1678, 1589, 1469,
1439, 1392, 1269, 1269, 1207, 1180, 1123, 1011, 991, 879, 852, 810, 771,
682, 651 cm−1; 1H NMR (500 MHz, CDCl3) δ 5.03 (s, 2H), 6.84 (dd, J
= 2.4, 8.1 Hz, 1H), 6.89 (dd, J = 1.2, 2.5 Hz, 1H), 6.98 (dt, J = 1.2, 7.6 Hz,
2H), 7.11 (d, J = 8.9 Hz), 7.18 (t, J = 7.8 Hz, 1H), 7.67 (dd, J = 2.6, 8.9
Hz, 1H), 7.96 (d, J = 2.7 Hz, 1H), 10.42 (s, 1H); 13C NMR (125 MHz,
CDCl3) δ 57.6 (CH2), 82.3 (C), 88.2 (C), 114.5 (C), 114.9 (C), 115.7
(CH), 116.6 (CH), 118.4 (CH), 122.7 (C), 124.3 (CH), 129.7 (CH),
131.2 (CH), 138.2 (CH), 155.5 (C), 158.9 (C), 188.6 (CH); EIMSm/z
329 (M+, 5), 277 (15), 219 (68), 199 (100), 130 (49); HREIMS
331.9885 (calcd for C16H11O3




lowing the general procedure, the treatment of 50 mg (0.21 mmol) of 5-
bromo-2-(prop-2-yn-1-yloxy)benzaldehyde with iodobenzene (29.0 μL,
0.27 mmol), Pd(PPh3)2Cl2 (4.4 mg, 3 mol %), CuI (2.5 mg, 6 mol %)
and piperidine (42 μL, 0.5 mmol) in dry THF (1 mL) under an Ar
atmosphere at 30 °C for 3 h, followed by evaporation of the solvent
under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 4:1) afforded 62.1 mg (94%) of
compound 6l38 as a yellow oil. IR (neat) νmax 2987, 2886, 2233, 1647,
1585, 1474, 1458, 1400, 1276, 1223, 1122, 1180, 1157, 1142, 1069, 995,
957, 887, 806, 752, 686, 652 cm−1; 1H NMR (500 MHz, CDCl3) δ 5.04
(s, 2H), 7.13 (d, J = 8.9 Hz, 1H), 7.33 (m, 3H), 7.42 (m, 2H), 7.66 (dd, J
= 2.6, 8.8 Hz, 1H), 7.97 (d, J = 2.6 Hz, 1H), 10.44 (s, 1H); 13C NMR
(125 MHz, CDCl3) δ 57.6 (CH2), 82.3 (C), 88.6 (C), 114.5 (C), 115.6
(CH), 121.7 (C), 126.9 (C), 128.4 (CH × 2), 129.1 (CH), 131.2 (CH),
131.8 (CH × 2), 138.1 (CH), 158.9 (C), 188.2 (CH); EIMS m/z 316
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(M+, 55), 287 (8), 235 (7), 207 (9), 115 (100); HREIMS 315.9923
(calcd for C16H11O2




(6m). Following the general procedure, the treatment of 50 mg (0.21
mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-nitro-1-
iodobenzene (54.9 mg, 0.27 mmol), Pd(PPh3)2Cl2 (4.4 mg, 3 mol %),
CuI (2.5 mg, 6 mol %) and piperidine (42 μL, 0.5 mmol) in dry THF (1
mL) under an Ar atmosphere at 30 °C for 3 h, followed by evaporation
of the solvent under reduced pressure and purification on silica gel
column chromatography (Hex/EtOAc, 7:3) afforded 66.9 mg (88%) of
compound 6m as a yellow oil. IR (neat) νmax 1682, 1589, 1524, 1466,
1393, 1342, 1273, 1219, 1177, 1119, 1018, 979, 879, 814, 733, 671, 652
cm−1; 1H NMR (500 MHz, CDCl3) δ 5.07 (s, 2H), 7.09 (d, J = 8.9 Hz,
1H), 7.52 (t, J = 8.0 Hz, 1H), 7.66 (dd, J = 2.6, 8.9 Hz, 1H), 7.72 (dt, J =
1.3, 7.7 Hz, 1H), 7.89 (d, J = 2.6 Hz, 1H), 8.21 (ddd, J = 1.0, 2.3, 8.3 Hz,
1H), 8.28 (t, J = 1.8 Hz, 1H), 10.44 (s, 1H); 13C NMR (125 MHz,
CDCl3) δ 57.3 (CH2), 85.0 (C), 86.0 (C), 114.8 (C), 115.3 (CH), 123.4
(C), 123.8 (CH), 124.9 (C), 126.7 (CH), 126.9 (C), 129.6 (CH), 131.4
(CH), 137.5 (CH), 138.2 (CH), 158.6 (C), 188.0 (CH); EIMSm/z 360
(M+, 9), 330 (3), 252 (5), 160 (100), 114 (56); HREIMS 360.9779
(calcd for C16H10NO4




benzaldehyde (6n). Following the general procedure, the treatment of
50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-trifluoromethyl-1-iodobenzene (31.8 μL, 0.27 mmol), Pd-
(PPh3)2Cl2 (4.4 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine
(42 μL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30 °C
for 3 h, followed by evaporation of the solvent under reduced pressure
and purification on silica gel column chromatography (Hex/EtOAc,
7:3) afforded 66.4 mg (82%) of compound 6n as a yellow oil. IR (neat)
νmax 1682, 1589, 1470, 1435, 1393, 1331, 1273, 1219, 1177, 1157, 1115,
1099, 1076, 1007, 972, 883, 806, 690, 660 cm−1; 1H NMR (500 MHz,
CDCl3) δ 5.05 (s, 2H), 7.09 (d, J = 8.9 Hz, 1H), 7.46 (t, J = 7.8 Hz, 1H),
7.59 (dd, J = 1.8, 7.7 Hz, 2H), 7.67 (m, 2H), 7.96 (d, J = 2.6 Hz, 1H),
10.43 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 57.4 (CH2), 84.0 (C),
86.9 (C), 114.6 (C), 115.3 (CH), 122.6 (C), 125.7 (CH, JC−F = 3.7 Hz),
127.9 (C, JC−F = 268.7 Hz), 128.6 (CH, JC−F = 3.9 Hz), 129.0 (CH),
131.1 (C, JC−F = 33.6 Hz), 130.4 (C), 131.3 (CH), 134.9 (CH), 138.1
(CH), 158.7 (C), 188.1 (CH); EIMS m/z 381 (M+, 25), 352 (8), 275
(11), 182 (100); HREIMS 383.9793 (calcd for C17H10F3O2
81Br
383.9796), 381.9824 (calcd. for C17H10F3O2
79Br 381.9816).
2-((3-(4-Methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6o).
Following the general procedure, the treatment of 50 mg (0.31
mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde with 4-iodoanisole (76.7
mg, 0.27 mmol), Pd(PPh3)2Cl2 (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol
%) and piperidine (60 μL, 0.5 mmol) in dry THF (1 mL) under an Ar
atmosphere at 30 °C for 3 h, followed by evaporation of the solvent
under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 53.0 mg (64%) of
compound 6o37 as a yellow oil. IR (neat) νmax 3521, 3398, 2237,
1682, 1597, 1508, 1458, 1223, 1099, 1030, 957, 825, 752, 640 cm−1; 1H
NMR (500 MHz, CDCl3) δ 3.80 (s, 3H), 5.04 (s, 2H), 6.83 (d, J = 8.7
Hz, 2H), 7.08 (t, J = 7.5 Hz, 1H), 7.21 (d, J = 8.4 Hz, 1H), 7.37 (d, J = 8.7
Hz, 2H), 7.57 (m, 1H), 7.87 (dd, J = 1.5, 7.7 Hz, 1H), 10.53 (s, 1H); 13C
NMR (125 MHz, CDCl3) δ 55.3 (CH3), 57.5 (CH2), 81.6 (C), 88.1
(C), 113.5 (CH), 113.9 (C), 114.0 (CH × 2), 121.5 (CH), 125.6 (C),
128.5 (CH), 133.4 (CH × 2), 135.7 (CH2), 160.1 (C), 160.2 (C), 189.8
(CH); EIMSm/z 266 (M+, 20), 237 (7), 145 (100), 102 (10); HREIMS
266.0945 (calcd for C17H14O3 (M
+) 266.0943).
2-((3-(3-Methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6p).
Following the general procedure, the treatment of 50 mg (0.31
mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde with 3-iodoanisole (39
μL, 0.32 mmol), Pd(PPh3)2Cl2 (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol
%) and piperidine (60 μL, 0.5 mmol) in dry THF (1 mL) under an Ar
atmosphere at 30 °C for 3 h, followed by evaporation of the solvent
under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 70.4 mg (85%) of
compound 6p as a yellow oil. IR (neat) νmax 1682, 1593, 1458, 1369,
1285, 1261, 1211, 1157, 1103, 1042, 1022, 987, 864, 833, 791, 764, 687,
648 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.78 (s, 3H), 5.04 (s, 2H),
6.89 (ddd, J = 0.9, 2.6, 8.3 Hz, 1H), 6.95 (dd, J = 1.4, 2.5 Hz, 1H), 7.02
(dt, J = 1.2, 7.7 Hz, 1H), 7.08 (m, 1H), 7.21 (m, 2H), 7.57 (ddd, J = 1.8,
7.3, 9.0 Hz, 1H), 7.87 (dd, J = 1.8, 7.7 Hz, 1H), 10.53 (s, 1H); 13C NMR
(125MHz, CDCl3) δ 55.2 (CH3), 57.3 (CH2), 82.7 (C), 88.0 (C), 113.4
(CH), 115.4 (CH), 116.7 (CH), 121.5 (CH), 122.8 (C), 124.2 (CH),
125.5 (C), 128.5 (CH), 129.4 (CH), 135.7 (CH), 159.3 (C), 160.0 (C),
189.6 (CH); EIMS m/z 266 (M+, 44), 237 (10), 145 (100), 102 (17);
HREIMS 266.0958 (calcd for C17H14O3 (M
+) 266.0943).
2-((3-(2-Methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6q).
Following the general procedure, the treatment of 50 mg (0.31
mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde with 2-iodoanisole (42.6
μL, 0.32 mmol), Pd(PPh3)2Cl2 (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol
%) and piperidine (60 μL, 0.5 mmol) in dry THF (1 mL) under an Ar
atmosphere at 30 °C for 3 h, followed by evaporation of the solvent
under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 50.0 mg (61%) of
compound 6q as a yellow oil. IR (neat) νmax 2233, 1686, 1597, 1481,
1458, 1369, 1265, 1250, 1215, 1161, 1099, 1018, 960, 833, 752, 694, 648
cm−1; 1HNMR (500MHz, CDCl3) δ 3.85 (s, 3H), 5.09 (s, 2H), 6.86 (d,
J = 8.4 Hz, 1H), 6.89 (td, J = 1.0, 7.5 Hz, 1H), 7.07 (m, 1H), 7.27 (d, J =
8.4 Hz, 1H), 7.30 (ddd, J = 1.8, 7.5, 9.2 Hz, 1H), 7.37 (dd, J = 1.7, 7.6 Hz,
1H), 7.57 (ddd, J = 1.9, 7.3, 9.1 Hz, 1H), 7.87 (dd, J = 1.8, 7.7 Hz, 1H),
10.54 (s, 1H); 13C NMR (125MHz, CDCl3) δ 55.7 (CH3), 57.6 (CH2),
84.6 (C), 86.9 (C), 110.6 (CH), 111.0 (C), 113.7 (CH), 120.4 (CH),
121.4 (CH), 125.5 (C), 128.3 (CH), 129.5 (C), 130.4 (CH), 133.7
(CH), 135.6 (CH), 160.2 (C), 189.8 (CH); EIMS m/z 266 (M+, 10),




Following the general procedure, the treatment of 50 mg (0.31
mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde with 3-iodophenol (72.1
mg, 0.32 mmol), Pd(PPh3)2Cl2 (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol
%) and piperidine (60 μL, 0.5 mmol) in dry THF (1 mL) under an Ar
atmosphere at 30 °C for 3 h, followed by evaporation of the solvent
under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 64.8 mg (78%) of
compound 6r. IR (neat) νmax 3398, 2924, 1682, 1597, 1470, 1288,
1211, 1053, 787, 756, 687, 652 cm−1; 1H NMR (500 MHz, CDCl3) δ
3.87 (s, 1H), 4.99 (s, 2H), 6.59 (ddd, J = 0.6, 2.1, 8.5 Hz, 1H), 6.67 (d, J =
2.2 Hz, 1H), 6.86 (dd, J = 1.8, 8.1 Hz, 1H), 6.93 (s, 1H), 6.97 (d, J = 7.8
Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 10.30 (s, 1H);
13C NMR (125 MHz, CDCl3) δ 57.4 (CH2), 82.9 (C), 87.7 (C), 113.6
(CH), 116.4 (CH), 118.4 (CH), 121.6 (CH), 123.0 (C), 124.4 (CH),
125.6 (C), 128.6 (CH), 129.7 (CH), 135.8 (CH), 155.4 (C), 160.1 (C),
189.9 (CH); HRESIMS 275.0688 (calcd. for C16H12O3Na 275.0684).
2-((3-Phenylprop-2-yn-1-yl)oxy)benzaldehyde (6s). Following the
general procedure, the treatment of 50 mg (0.31 mmol) of 2-(prop-2-
yn-1-yloxy)benzaldehyde (0.31 mmol) with iodobenzene (43.1 μL, 0.32
mmol), Pd(PPh3)2Cl2 (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and
piperidine (60 μL, 0.5 mmol) in dry THF (1 mL) under an Ar
atmosphere at 30 °C for 3 h, followed by evaporation of the solvent
under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 56.8 mg (78%) of
compound 6s.39 IR (neat) νmax 1678, 1659, 1593, 1481, 1458, 1400,
1373, 1285, 1261, 1218, 1192, 1165, 1107, 1042, 995, 957, 914, 829, 756,
725, 687, 652, 609 cm−1. 1H-RMN (500 MHz, CDCl3) δ 5.05 (s, 2H),
7.09 (t, J = 7.0 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 7.32 (m, 3H), 7.43 (m,
2H), 7.58 (ddd, J = 1.8, 7.5, 9.0 Hz, 1H), 7.88 (dd, J = 1.7, 7.7 Hz, 1H),
10.54 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 57.3 (CH2), 82.9 (C),
88.1 (C), 113.4 (CH), 121.5 (CH), 121.9 (C), 125.6 (C), 128.3 (CH ×
2), 128.5 (CH), 128.9 (CH), 131.8 (CH × 2), 135.7 (CH), 160.1 (C),
189.7 (CH); EIMS m/z 236 (M+, 77), 206 (50), 120 (45), 114 (100);
HREIMS 236.0836 (calcd for C16H12O2 (M
+) 236.0837).
2-((3-(3-Nitrophenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6t). Fol-
lowing the general procedure, the treatment of 50 mg (0.31 mmol) of 2-
(prop-2-yn-1-yloxy)benzaldehyde (0.31 mmol) with 3-nitro-1-iodo-
benzene (81.6 mg, 0.32 mmol), Pd(PPh3)2Cl2 (6.6 mg, 3 mol %), CuI
(3.6 mg, 6 mol %) and piperidine (60 μL, 0.5 mmol) in dry THF (1 mL)
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under an Ar atmosphere at 30 °C for 3 h, followed by evaporation of the
solvent under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 73.2 mg (84%) of
compound 6t. IR (neat) νmax 1678, 1593, 1535, 1481, 1458, 1369,
1346, 1285, 1234, 1161, 1103, 1022, 999, 879, 844, 810, 764, 733, 667
cm−1; 1H NMR (500 MHz, CDCl3) δ 5.07 (s, 2H), 7.11 (m, 1H), 7.17
(d, J = 8.4 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.60 (ddd, J = 1.9, 7.3, 9.1
Hz, 1H), 7.72 (td, J = 1.3, 7.8 Hz, 1H), 7.88 (dd, J = 1.8, 7.7 Hz, 1H),
8.18 (ddd, J = 1.1, 2.3, 8.4 Hz, 1H), 8.26 (t, J = 1.8 Hz, 1H), 10.52 (s,
1H); 13C NMR (125 MHz, CDCl3) δ 56.9 (CH2), 85.5 (C), 85.6 (C),
113.2 (CH), 121.8 (CH), 123.6 (CH), 125.6 (C), 126.6 (CH), 128.7
(CH), 129.5 (CH), 130.2 (C), 135.8 (CH), 137.4 (CH), 148.1 (C),
159.8 (C), 189.4 (CH); EIMSm/z 281 (M+, 45), 252 (14), 234 (8), 159




(6u). Following the general procedure, the treatment of 50 mg (0.31
mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde (0.31 mmol) with 3-
trifluoromethyl-1-iodobenzene (42.3 μL, 0.32 mmol), Pd(PPh3)2Cl2
(6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and piperidine (60 μL, 0.5
mmol) in dry THF (1 mL) under an Ar atmosphere at 30 °C for 3 h,
followed by evaporation of the solvent under reduced pressure and
purification on silica gel column chromatography (hex/EtOAc, 7:3)
afforded 81.1 mg (86%) of compound 6u as a yellow oil. IR (neat) νmax
1678, 1597, 1481, 1458, 1396, 1331, 1288, 1219, 1157, 1119, 1072,
1011, 976, 903, 833, 798, 760, 690, 660 cm−1; 1H NMR (500 MHz,
CDCl3) δ 5.06 (s, 2H), 7.10 (t, J = 7.5 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H),
7.44 (t, J = 7.8 Hz, 2H), 7.59 (m, 3H), 7.68 (s, 1H), 7.88 (dd, J = 1.4, 7.7
Hz, 1H), 10.53 (s, 1H);13C NMR (125 MHz, CDCl3) δ 57.1 (CH2),
84.6 (C), 86.4 (C), 113.3 (CH), 121.7 (CH), 122.8 (C), 123.5 (C, JC−F
= 274.6 Hz), 125.5 (CH, JC−F = 3.5 Hz), 125.6 (C), 128.6 (CH, JC−F =
3.8 Hz), 128.7 (CH), 128.9 (CH), 131.0 (C, JC−F = 30.6 Hz), 134.9
(CH), 135.8 (CH), 159.9 (C), 189.5 (CH); EIMS m/z 304 (M+, 27),
276 (7), 183 (100), 133 (3); HREIMS 304.0718 (calcd for C17H11O2F3
(M+) 304.0711).
4-Methoxy-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde (6v). Following the general procedure, the treatment of
50 mg (0.26 mmol) of of 4-methoxy-2-(prop-2-yn-1-yloxy)-
benzaldehyde with 4-iodoanisole (64.6 mg, 0.27 mmol), Pd(PPh3)2Cl2
(5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 μL, 0.5
mmol) in dry THF (1 mL) under an Ar atmosphere at 30 °C for 4.5 h,
followed by evaporation of the solvent under reduced pressure and
purification on silica gel column chromatography (Hex: EtOAc, 7:3)
afforded 63.5 mg (82%) of compound 6v as a yellow oil. IR (neat) νmax
1666, 1601, 1504, 1454, 1439, 1381, 1315, 1288, 1265, 1207, 1169,
1111, 1057, 1011, 953, 868, 825, 794, 675 cm−1; 1H NMR (500 MHz,
CDCl3) δ 3.80 (s, 3H), 3.88 (s, 3H), 5.01 (s, 2H), 6.60 (dd, J = 2.2, 8.7
Hz, 1H), 6.69 (d, J = 2.2 Hz, 2H), 6.84 (d, J = 8.7, 2H), 7.37 (d, J = 8.7
Hz, 2H), 7.84 (d, J = 8.7 Hz, 1H), 10.34 (s, 1H); 13C NMR (125 MHz,
CDCl3) δ 55.3 (CH3), 55.7 (CH3), 57.5 (CH2), 81.5 (C), 88.3 (C), 99.6
(CH), 106.8 (CH), 113.9 (C), 114.0 (CH × 2), 119.6 (C), 130.5 (CH),
133.4 (CH × 2), 160.1 (C), 161.9 (C), 165.9 (C), 188.3 (CH); EIMS
m/z 296 (M+, 11), 267 (7), 237 (1), 144 (100), 102 (11); HREIMS
296.1041 (calcd for C18H16O4 (M
+) 296.1049).
4-Methoxy-2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde (6w). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-iodoanisole (32.8 μL, 0.27 mmol), Pd(PPh3)2Cl2 (5.5 mg, 3 mol
%), CuI (2.9 mg, 6 mol %) and piperidine (51 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 65 mg
(84%) of compound 6w of yellow oil. IR (neat) νmax 1674, 1601, 1577,
1485, 1439, 1373, 1315, 1261, 1204, 1168, 1107, 1034, 991, 933, 860,
825, 771, 744, 683 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.79 (s, 3H),
3.88 (s, 3H), 5.02 (s, 2H), 6.60 (ddd, J = 0.5, 2.2, 8.9 Hz, 1H), 6.68 (d, J =
2.5 Hz, 1H), 6.90 (ddd, J = 0.9, 2.7, 8.3 Hz, 1H), 6.96 (dd, J = 1.5, 2.6 Hz,
1H), 7.03 (dt, J = 1.1, 7.5 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.85 (d, J =
8.6 Hz, 1H), 10.35 (s, 1H); 13CNMR (125MHz, CDCl3) δ 55.3 (CH3),
55.7 (CH3), 57.3 (CH2), 82.6 (C), 88.1 (C), 99.6 (CH), 106.8 (CH),
115.5 (CH), 119.7 (CH), 119.6 (C), 122.9 (C), 124.3 (CH), 129.5
(CH), 130.6 (CH), 159.3 (C), 161.8 (C), 165.9 (C), 188.3 (CH); EIMS
m/z 296 (M+, 64), 268 (67), 237 (10), 145 (100), 102 (66); HREIMS
296.1044 (calcd for C18H16O4 (M
+) 296.1049).
4-Methoxy-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde (6x). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde
with 2-iodoanisole (35.9 μL, 0.27 mmol), Pd(PPh3)2Cl2 (5.5 mg, 3 mol
%), CuI (2.9 mg, 6mol %) and piperidine (51 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 43.3 mg
(56%) of compound 6x. IR (neat) νmax 2839, 2233, 1674, 1597, 1493,
1435, 1258, 1161, 1107, 1014, 825, 752, 683, 644 cm−1; 1H NMR (500
MHz, CDCl3) δ 3.85 (s, 3H), 3.89 (s, 3H), 5.07 (s, 2H), 6.60 (dd, J = 1.6,
8.6 Hz, 1H), 6.77 (d, J = 2.0 Hz, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.89 (t, J =
7.8 Hz, 1H), 7.3 (td, J = 1.3, 7.9 Hz, 1H), 7.40 (dd, J = 1.4, 7.6 Hz, 1H),
7.83 (d, J= 8.7 Hz, 1H), 10.35 (s, 1H); 13C NMR (125 MHz, CDCl3) δ
55.6 (CH3), 55.7 (CH3), 57.6 (CH2), 84.8 (C), 86.8 (C), 99.7 (CH),
107.0 (CH), 110.7 (CH), 120.4 (CH), 127.6 (C), 130.4 (CH), 130.5
(CH), 133.8 (CH), 135.2 (C), 160.4 (C), 162.0 (C), 165.9 (C), 188.4
(CH); EIMS m/z 296 (M+, 21), 268 (34), 262 (27), 145 (100), 115
(64); HREIMS 296.1042 (calcd for C18H16O4 (M
+) 296.1049).
4-Methoxy-2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde (6y). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-iodophenol (60.7 mg, 0.27 mmol), Pd(PPh3)2Cl2 (5.5 mg, 3 mol
%), CuI (2.9 mg, 6mol %) and piperidine (51 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 44.7 mg
(61%) of compound 6y as a yellow oil. IR (neat) νmax 3205, 2939, 2847,
2230, 1666, 1601, 1574, 1497, 1393, 1292, 1261, 1173, 1134, 1119,
1022, 991, 864, 837, 683 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.87 (s,
1H), 4.99 (s, 2H), 6.59 (ddd, J = 0.6, 2.1, 8.5 Hz, 1H), 6.67 (d, J = 2.2 Hz,
1H), 6.86 (dd, J = 1.8, 8.1 Hz, 1H), 6.93 (s, 1H), 6.97 (d, J = 7.8 Hz, 1H),
7.15 (t, J = 7.9 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 10.30 (s, 1H); 13C
NMR (125 MHz, CDCl3) δ 55.7 (CH3), 57.4 (CH2), 82.5 (C), 88.1
(C), 99.6 (CH), 107.1 (CH), 116.6 (CH), 118.5 (CH), 119.4 (C),
122.8 (C), 124.0 (CH), 129.6 (CH), 130.8 (CH), 155.9 (C), 162.0 (C),
166.2 (C), 188.9 (CH); EIMSm/z 282 (M+, 15), 254 (24), 223 (4), 151




Following the general procedure, the treatment of 50 mg (0.26
mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde (0.26 mmol)
with 3-iodobenzene (36.3 μL, 0.27mmol), Pd(PPh3)2Cl2 (5.5 mg, 3 mol
%), CuI (2.9 mg, 6mol %) and piperidine (51 μL, 0.5 mmol) in dry THF
(1 mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 60.5 mg
(87%) of compound 6z as a yellow oil. IR (neat) νmax 1674, 1597, 1492,
1443, 1373, 1258, 1191, 1157, 1092, 1157, 1092, 1030, 964, 822, 756,
690 cm−1;1H NMR (500 MHz, CDCl3) δ 3.88 (s, 3H), 5.02 (s, 2H),
6.60 (ddd, J = 0.4, 2.1, 6.5 Hz, 1H), 6.69 (d, J = 2.2 Hz, 1H), 7.33 (m,
3H), 7.43 (m, 2H), 7.85 (d, J = 8.7 Hz, 1H), 10.35 (s, 1H); 13C NMR
(125 MHz, CDCl3) δ 55.7 (CH3), 57.3 (CH2), 82.8 (C), 88.2 (C), 99.5
(CH), 106.8 (CH), 119.6 (C), 121.9 (C), 128.4 (CH × 2), 128.9 (CH),
130.6 (CH), 131.8 (CH × 2), 161.8 (C), 165.9 (C), 188.2 (CH); EIMS
m/z 266 (M+, 11), 238 (20), 207 (3), 151 (7), 115 (100); HREIMS
266.0934 (calcd for C17H14O3 (M
+) 266.0943).
4-Methoxy-2- ( (3- (3-n i t rophenyl )prop-2-yn-1-y l )oxy)-
benzaldehyde (6aa). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde
with 3-nitro-1-iodo-benzene (36.3 μL, 0.27 mmol), Pd(PPh3)2Cl2 (5.5
mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 μL, 0.5 mmol)
in dry THF (1mL) under an Ar atmosphere at 30 °C for 3 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (hex/EtOAc, 7:3) afforded 79.1 mg
(98%) of compound 6aa as a yellow oil. IR (neat) νmax 1678, 1605, 1527,
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1501, 1462, 1439, 1373, 1353, 1261, 1196, 1165, 1111, 1026, 945, 906,
829, 806, 737, 671 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.89 (s, 3H),
5.04 (s, 2H), 6.63 (m, 2H), 7.51 (t, J = 7.9 Hz, 1H), 7.74 (dt, J = 1.3, 7.8
Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 8.20 (ddd, J = 1.0, 2.3, 8.3 Hz, 1H),
8.28 (t, J = 1.8 Hz, 1H), 10.34 (s, 1H); 13C NMR (125 MHz, CDCl3) δ
55.2 (CH3), 56.9 (CH2), 85.5 (C), 85.5 (C), 99.6 (CH), 106.7 (CH),
119.5 (C), 123.6 (CH), 126.6 (CH), 129.5 (CH), 130.8 (CH), 137.4
(CH), 148.0 (C), 161.4 (C), 165.9 (C), 188.0 (CH); EIMS m/z 311
(M+, 9), 283 (84), 236 (9), 160 (100), 133 (30), 114 (75); HREIMS
311.0791 (calcd for C17H13O5N (M
+) 311.0794).
4-Methoxy-2-((3-(3-trifluoromethylphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde (6ab). Following the general procedure, the treatment of
50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde
(0.26 mmol) with 3-trifluoromethyl-1-iodobenzene (39.8 μL, 0.27
mmol), Pd(PPh3)2Cl2 (5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and
piperidine (51 μL, 0.5 mmol) in dry THF (1 mL) under an Ar
atmosphere at 30 °C for 3 h, followed by evaporation of the solvent
under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 75.5 mg (87%) of
compound 6ab as a yellow oil. IR (neat) νmax 1663, 1597, 1504, 1462,
1435, 1389, 1327, 1258, 1204, 1153, 1119, 1096, 1069, 1026, 999, 906,
833, 798, 740, 698, 663 cm−1; 1H NMR (500 MHz, CDCl3) δ 3.89 (s,
1H), 5.03 (s, 2H), 6.62 (dd, J = 2.1, 8.7 Hz, 1H), 6.66 (d, J = 2.6Hz, 1H),
7.45 (t, J = 7.8 Hz, 1H), 7.59 (t, J = 6.3 Hz, 2H), 7.70 (s, 1H), 7.86 (d, J =
8.8 Hz, 1H), 10.35 (s, 1H);13C NMR (125MHz, CDCl3) δ 57.1 (CH2),
84.6 (C), 86.44 (C), 113.3 (CH), 121.7 (CH), 122.8 (C), 123.5 (C, JC−F
= 274.6 Hz), 125.5 (CH, JC−F = 3.5 Hz), 125.6 (C), 128.6 (CH, JC−F =
3.8 Hz), 128.7 (CH), 128.9 (CH), 131.0 (C, JC−F = 30.6 Hz), 134.9
(CH), 135.8 (CH), 159.9 (C), 189.5 (CH); EIMS m/z 334 (M+, 21),




benzoate (6ac). Following the general procedure, the treatment of 50
mg (0.23 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with
4-iodoanisole (52.9 mg, 0.32 mmol), Pd(PPh3)2Cl2 (4.8 mg, 3 mol %),
CuI (2.5 mg, 6 mol %) and piperidine (51 μL, 0.5 mmol) in dry THF (1
mL) under an Ar atmosphere at 30 °C for 3 h, followed by evaporation
of the solvent under reduced pressure and purification on silica gel
column chromatography (Hex/EtOAc, 7:3) afforded 61.6 mg (83%) of
compound 6ac as a yellow oil. IR (neat) νmax 3522, 3398, 2893, 2225,
1701, 1605, 1500, 1366, 1246, 1177, 1142, 1126, 1045, 1026, 829, 764,
690 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.38 (t, J = 7.1 Hz, 3H), 3.79
(s, 3H), 4.37 (q, J = 7.1 Hz, 2H), 5.09 (s, 2H), 6.82 (d, J = 8.8 Hz, 2H),
7.26 (d, J = 8.8 Hz, 1H), 7.35 (d, J = 8.8, 2H), 8.26 (dd, J = 2.4, 8.8 Hz,
1H), 8.52 (d, J = 2.3 Hz, 1H), 10.50 (s, 1H); 13C NMR (125 MHz,
CDCl3) δ 14.3 (CH3), 55.3 (CH3), 57.8 (CH2), 61.1 (CH2), 80.9 (C),
88.9 (C), 113.3 (CH), 113.8 (C), 114.2 (CH× 2), 124.2 (C), 125.3 (C),
130.5 (CH), 133.4 (CH × 2), 136.7 (CH), 160.4 (C), 163.0 (C), 165.5
(C), 188.7 (CH); EIMS m/z 338 (M+, 61), 309 (21), 262 (22), 145




benzoate (6ad). Following the general procedure, the treatment of
50 mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate
with 3-iodoanisole (26.9 μL, 0.23 mmol), Pd(PPh3)2Cl2 (4.8 mg, 3 mol
%), CuI (2.5 mg, 6 mol %) and piperidine (43 μL, 0.43 mmol) in dry
THF (1 mL) under an Ar atmosphere at 30 °C for 1.5 h, followed by
evaporation of the solvent under reduced pressure and purification on
silica gel column chromatography (Hex/EtOAc, 7:3) afforded 71.9 mg
(97%) of compound 6ad as a yellow oil. IR (neat) νmax 2885, 2858, 2237,
1701, 1605, 1492, 1377, 1292, 1238, 1188, 1142, 1018, 984, 849, 768,
687, 659, 629 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.38 (t, J = 7.2 Hz,
3H), 3.77 (s, 3H), 4.37 (q, J = 7.2 Hz, 2H), 5.10 (s, 2H), 6.89 (ddd, J =
0.8, 2.6, 8.3 Hz, 1H), 6.94 (dd, J = 1.2, 2.6 Hz, 1H), 7.00 (dt, J = 0.8, 7.5
Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 7.25 (d, J = 8.8 Hz, 1H), 8.26 (dd, J =
2.3, 8.8 Hz, 1H), 8.50 (d, J = 2.3 Hz, 1H), 10.50 (s, 1H);13C NMR (125
MHz, CDCl3) δ 14.3 (CH3), 55.3 (CH3), 57.6 (CH2), 61.1 (CH2), 82.0
(C), 88.7 (C), 113.2 (CH), 115.7 (CH), 116.9 (CH), 122.7 (C), 124.3
(C), 124.4 (CH), 125.3 (C), 129.5 (CH), 130.6 (CH), 136.7 (CH),
159.5 (C), 162.9 (C), 165.4 (C), 188.6 (CH); EIMSm/z 338 (M+, 65),
309 (11), 293 (11), 145 (100), 115 (24), 102 (46); HREIMS 338.1168
(calcd for C20H18O5 (M
+) 338.1154).
Ethyl 4-formyl-3-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)-
benzoate (6ae). Following the general procedure, the treatment of 50
mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with
2-iodoanisole (26.4 μL, 0.23 mmol), Pd(PPh3)2Cl2 (4.8 mg, 3 mol %),
CuI (2.5 mg, 6mol %) and piperidine (43 μL, 0.43mmol) in dry THF (1
mL) under an Ar atmosphere at 30 °C for 1.5 h, followed by evaporation
of the solvent under reduced pressure and purification on silica gel
column chromatography (Hex/EtOAc, 7:3) afforded 44.2 mg (59%) of
compound 6ae as a yellow oil. IR (neat) νmax 3533, 2977, 2233, 1708,
1686, 1605, 1493, 1369, 1304, 1242, 1169, 1103, 1022, 995, 941, 829,
760, 748, 694 cm−1; 1H NMR (500 MHz, CDCl3) δ 1.39 (t, J = 7.2 Hz,
3H), 3.84 (s, 3H), 4.38 (q, J = 7.2 Hz, 2H), 5.15 (s, 2H), 6.86 (d, J = 8.1
Hz, 1H), 6.89 (dd, J = 0.9, 7.6 Hz, 1H), 7.30 (ddd, J = 1.7, 7.7, 9.2 Hz,
1H), 7.33 (d, J = 8.8 Hz, 1H), 7.36 (dd, J = 1.7, 7.5 Hz, 1H), 8.26 (dd, J =
2.2, 8.7 Hz, 1H), 8.53 (d, J = 2.2 Hz, 1H), 10.51 (s, 1H); 13C NMR (125
MHz, CDCl3) δ 14.3 (CH3), 55.8 (CH3), 58.0 (CH2), 61.1 (CH2), 85.5
(C), 86.2 (C), 111.0 (CH), 111.1 (C), 113.7 (CH), 120.5 (CH), 124.2
(C), 125.4 (C), 130.4 (CH), 130.6 (CH), 133.8 (CH), 136.7 (CH),
160.6 (C), 163.1 (C), 165.5 (C), 188.8 (CH); EIMSm/z 338 (M+, 17),
320 (22), 262 (31), 183 (19), 145 (100), 115 (79); HREIMS 338.1168
(calcd for C20H18O5 (M
+) 338.1154).
Ethyl 4-formyl-3-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)-
benzoate (6af). Following the general procedure, the treatment of 50
mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with
3-iodophenol (49.7 mg, 0.23 mmol), Pd(PPh3)2Cl2 (4.8 mg, 3 mol %),
CuI (2.5 mg, 6mol %) and piperidine (43 μL, 0.43mmol) in dry THF (1
mL) under an Ar atmosphere at 30 °C for 1.5 h, followed by evaporation
of the solvent under reduced pressure and purification on silica gel
column chromatography (Hex/EtOAc, 7:3) afforded 39.5 mg (55%) of
compound 6af as a yellow oil. IR (neat) νmax 3391, 3028, 1686, 1601,
1489, 1443, 1296, 1261, 1180, 1103, 1018, 984, 957, 868, 768, 687, 656
cm−1; 1H NMR (500 MHz, CDCl3) δ 1.38 (t, J = 7.3 Hz, 3H), 4.37 (q, J
= 7.1 Hz, 2H), 4.95 (s, 1H), 5.09 (s, 1H), 6.83 (ddd, J = 1.1, 2.9, 8.3 Hz,
1H), 6.89 (dd, J = 1.1, 2.4 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 7.16 (t, J =
7.8 Hz, 1H), 7.24 (s, 1H), 8.26 (dd, J = 2.2, 8.7 Hz, 1H), 8.52 (d, J = 2.2
Hz, 1H), 10.49 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 14.3 (CH3),
57.5 (CH3), 61.3 (CH2), 82.0 (C), 88.5 (C), 113.2 (CH), 115.0 (C),
116.7 (CH), 118.5 (CH), 122.7 (C), 124.3 (CH), 124.9 (C), 129.7
(CH), 130.7 (CH), 137.0 (CH), 155.6 (C), 162.9 (C), 165.7 (C), 189.1
(C); EIMSm/z 324 (M+, 22), 262 (41), 182 (24), 131 (100); HREIMS
324.1024 (calcd. for C19H16O5 (M
+) 324.0998).
Ethyl 4-formyl-3-((3-phenylprop-2-yn-1-yl)oxy)benzoate (6ag).
Following the general procedure, the treatment of 50 mg (0.22
mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with iodophe-
nol (29.7 μL, 0.23 mmol), Pd(PPh3)2Cl2 (4.8 mg, 3 mol %), CuI (2.5
mg, 6 mol %) and piperidine (43 μL, 0.43 mmol) in dry THF (1 mL)
under an Ar atmosphere at 30 °C for 1.5 h, followed by evaporation of
the solvent under reduced pressure and purification on silica gel column
chromatography (Hex/EtOAc, 7:3) afforded 66.2 mg (98%) of
compound 6ag as a yellow oil. IR (neat) νmax 2989, 2858, 1705, 1605,
1493, 1443, 1366, 1254, 1188, 1149, 1014, 995, 848, 756, 687, 663, 648
cm−1; 1H NMR (500 MHz, CDCl3) δ 1.39 (t, J = 7.1 Hz, 3H), 4.36 (q, J
= 7.1 Hz, 2H), 5.11 (s, 2H), 7.29 (m, 4H), 7.41 (m, 2H), 7.26 (dd, J =
2.2, 8.8 Hz, 1H), 8.53 (d, J = 2.3 Hz, 1H), 10.51 (s, 1H); 13C NMR (125
MHz, CDCl3) δ 14.3 (CH3), 57.7 (CH2), 61.1 (CH2), 82.3 (C), 88.8
(C), 113.3 (CH), 121.8 (C), 123.3 (C), 125.4 (C), 128.4 (CH × 2),
129.1 (CH), 130.6 (CH), 131.8 (CH × 2), 136.7 (CH), 162.9 (C),
165.4 (C), 188.6 (CH); EIMS m/z 308 (M+, 100), 263 (27), 193 (16),




(6ah). Following the general procedure, the treatment of 50 mg (0.22
mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with 3-nitro-1-
iodo-benzene (56.3 mg, 0.23 mmol), Pd(PPh3)2Cl2 (4.8 mg, 3 mol %),
CuI (2.5 mg, 6mol %) and piperidine (43 μL, 0.43mmol) in dry THF (1
mL) under an Ar atmosphere at 30 °C for 1.5 h, followed by evaporation
of the solvent under reduced pressure and purification on silica gel
column chromatography (hex/EtOAc, 7:3) afforded 69.6 mg (90%) of
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compound 6ah as a yellow oil. IR (neat) νmax 3521, 3398, 1686, 1609,
1531, 1366, 1057, 987, 848, 725, 667 cm−1; 1H NMR (500 MHz,
CDCl3) δ 1.37 (t, J = 7.2 Hz, 3H), 4.36 (q, J = 7.2 Hz, 2H), 5.14 (s, 2H),
7.23 (d, J = 8.8 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.70 (dt, J = 1.2, 7.7 Hz,
1H), 8.17 (ddd, J = 1.0, 2.3, 8.4 Hz, 1H), 8.24 (t, J = 1.8 Hz, 1H), 8.26
(dd, J = 2.3, 8.8 Hz, 1H), 8.51 (d, J = 2.2 Hz, 1H), 10.49 (s, 1H); 13C
NMR (125 MHz, CDCl3) δ 14.3 (CH3), 57.2 (CH2), 61.1 (CH2), 84.9
(C), 86.1 (C), 114.0 (CH), 123.5 (C), 123.8 (CH), 124.5 (C), 125.3
(C), 126.6 (CH), 129.5 (CH), 130.7 (CH), 136.8 (CH), 137.4 (CH),
148.2 (C), 162.6 (C), 165.3 (C), 188.4 (CH); EIMSm/z 353 (M+, 20),
308 (11), 279 (4), 206 (7), 160 (100), 114 (36); HREIMS 353.0915
(calcd. for C19H15O6N (M
+) 353.0899).
Ethyl 4-formyl-3-((3-(3-trifluoromethylphenyl)prop-2-yn-1-yl)-
oxy)benzoate (6ai). Following the general procedure, the treatment
of 50 mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate
with 3-trifluoromethyl-1-iodobenzene (56.3 mg, 0.23 mmol), Pd-
(PPh3)2Cl2 (4.8 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine
(43 μL, 0.43 mmol) in dry THF (1 mL) under an Ar atmosphere at 30
°C for 1.5 h, followed by evaporation of the solvent under reduced
pressure and purification on silica gel column chromatography (Hex/
EtOAc, 7:3) afforded 83.7 mg (100%) of compound 6ai as a yellow oil.
IR (neat) νmax 3514, 3402, 1712, 1689, 1612, 1434, 1385, 1319, 1061,
968, 825, 687, 667, 629 cm−1; 1HNMR (500MHz, CDCl3) δ 1.38 (t, J =
7.4 Hz, 3H), 4.37 (q, J = 7.1 Hz, 2H), 5.12 (s, 2H), 7.23 (d, J = 8.9 Hz,
1H), 7.43 (t, J = 7.8 Hz, 1H), 7.57 (s, 1H), 7.59 (s, 1H), 7.67 (s, 1H),
8.23 (dd, J = 2.2, 8.7 Hz, 1H), 8.53 (d, J = 2.2Hz, 1H), 10.50 (s, 1H); 13C
NMR (125 MHz, CDCl3) δ 55.7 (CH3), 57.1 (CH2), 84.4 (C), 86.6
(C), 99.6 (CH), 106.7 (CH), 119.6 (C), 122.8 (C), 123.5 (C, JC−F =
275.5 Hz), 125.5 (CH, JC−F = 3.6 Hz), 128.6 (CH, JC−F = 3.0 Hz), 129.0
(CH), 130.8 (CH), 131.0 (C, JC−F = 33.4 Hz), 134.9 (CH), 160.6 (C),
165.9 (C), 188.1 (CH); EIMS m/z 376 (M+, 21), 347 (8), 330 (5), 275
(4), 182 (100); HREIMS 376.0911 (calcd. for C20H15O4F3 (M
+)
376.0922).
General Procedures for the Preparation of Pyran Embelin
Derivatives via DKHDA. A solution of embelin (30.0 mg, 0.10 mmol)
in dichloroethane (5 mL), 0.15 mmol of the corresponding alkyne and
10mol % of EDDAwas placed in amicrowave-special closed vial and the
solution was irradiated for 10 min in a single-mode microwave oven
(120 °C). The reaction mixture was then cooled to room temperature.
After removal of the solvent under reduced pressure, the product was
purified by preparative TLC using Hex/EtOAc to yield the
corresponding pyran derivatives.
11-Chloro-2-hydroxy-6-(4-methoxyphenyl)-3-undecylchromeno-
[3,4-c]chromene-1,4(7H,12bH)-dione (7a). Following the general
procedure described above, 26.1 mg (0.09 mmol) of embelin, 40 mg
(0.1 mmol) of 5-chloro-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde and 1.02 mg of EDDA (10 mol %) were suspended in 2
mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C.
The crude was purified by preparative TLC with 30% Hex/EtOAc to
provide 47.8 mg (93%) of 7a as a brown solid. mp 148.8−149.4 °C; IR
(neat) νmax 3348, 2923, 2853, 1687, 1651, 1619, 1608, 1513, 1479, 1400,
1345, 1323, 1305, 1248, 1220, 1172, 1116, 1085, 1023, 983, 870, 842,
814 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 6.9 Hz, 3H), 1.25
(bs, 16H), 1.50 (m, 2H), 2.50 (t, J = 7.7 Hz, 2H), 3.83 (s, 3H), 4.82 (s,
1H), 4.86 (d, J = 12.6 Hz, 1H), 4.89 (d, J = 12.9 Hz, 1H), 6.65 (d, J = 1.4
Hz, 1H), 6.76 (d, J = 8.8 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 7.09 (dd, J =
1.9, 8.8 Hz, 1H), 7.33 (d, J = 8.6 Hz, 2H); 13C NMR (125MHz, CDCl3)
δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4
(CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2 × 2), 30.9 (CH), 31.9
(CH2), 55.4 (CH3), 67.8 (CH2), 106.8 (C), 110.5 (C), 113.9 (CH× 2),
118.9 (CH), 119.6 (C), 123.4 (C), 123.6 (C), 125.3 (CH), 125.9 (C),
128.2 (CH), 129.0 (C), 129.9 (CH × 2), 145.2 (C), 152.2 (C), 152.6
(C), 160.8 (C), 180.0 (C), 183.3 (C); EIMS m/z 576 (M+, 100), 548
(22), 436 (20), 407 (39), 283 (51), 135 (87); HREIMS 578.2284 (calcd
for C34H37O6




[3,4-c]chromene-1,4(7H,12bH)-dione (7b). Following the general
procedure described above, 45.6 mg (0.16 mmol) of embelin, 70 mg
(0.23 mmol) of 5-chloro-2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)-
oxy)benzaldehyde and 2.8 mg of EDDA (10 mol %) were suspended
in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120
°C. The crude was purified by preparative TLCwith 30%Hex/EtOAc to
provide 90.4 mg (98%) of 7b as a brown solid. mp 81.8−82.9 °C; IR
(neat) νmax 3315, 2924, 2853, 1640, 1625, 1598, 1480, 1431, 1345, 1261,
1177, 1119, 1092, 1043, 1024, 990, 887, 819 cm−1; 1H NMR (500MHz,
CDCl3) δ 0.87 (t, J = 7.2 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t,
J = 7.7 Hz, 2H), 3.82 (s, 3H), 4.83 (s, 1H), 4.88 (s, 2H), 6.66 (d, J = 1.5
Hz, 1H), 6.76 (d, J = 8.6 Hz, 1H), 6.94 (m, 3H), 7.10 (dd, J = 2.2, 8.7 Hz,
1H), 7.32 (t, J = 7.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 14.1
(CH3), 22.7 (2 ×CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.6 (2 ×
CH2), 29.7 (2×CH2), 30.9 (CH), 31.9 (CH2), 55.4 (CH3), 67.7 (CH2),
108.1 (C), 110.5 (C), 113.9 (CH), 115.8 (CH), 116.8 (C), 118.9 (CH),
119.7 (C), 120.9 (CH), 125.3 (CH), 126.0 (C), 128.3 (CH), 129.0 (C),
129.6 (CH), 132.4 (C), 145.1 (C), 152.1 (C), 152.6 (C), 159.6 (C),
179.9 (C), 183.4 (C); EIMSm/z 578 (M+, 16), 558 (10), 481 (34), 338
(12), 135 (100); HREIMS 576.2268 (calcd for C34H37O6
35Cl
576.2279), 578.2264 (calcd for C34H37O6
35Cl 578.2249).
11-Chloro-2-hydroxy-6-(2-methoxyphenyl)-3-undecylchromeno-
[3,4-c]chromene-1,4(7H,12bH)-dione (7c). Following the general
procedure described above, 32.6 mg (0.11 mmol) of embelin, 50 mg
(0.17 mmol) of 5-chloro-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)-
oxy)benzaldehyde and 2.8 mg of EDDA (10 mol %) were suspended
in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120
°C. The crude was purified by preparative TLCwith 30%Hex/EtOAc to
provide 41.5 mg (65%) of 7c as a brown solid. mp 121.5−122.8 °C; IR
(neat) νmax 3363, 2924, 2853, 2360, 2338, 1697, 1652, 1620, 1600, 1479,
1348, 1254, 1229, 1178, 1118, 1089, 1049, 1019, 989, 820 cm−1;1H
NMR (500MHz, CDCl3) δ 0.87 (t, J = 7.1 Hz, 3H), 1.25 (bs, 16H), 1.50
(m, 2H), 2.48 (t, J = 7.4 Hz, 2H), 3.79 (s, 3H), 4.47 (d, J = 12.5 Hz, 1H),
4.74 (d, J = 13.0 Hz, 1H), 4.83 (s, 1H), 6.67 (s, 1H), 6.73 (d, J = 8.6 Hz,
1H), 6.93 (d, J = 8.5Hz, 1H), 6.99 (t, J = 7.3 Hz, 1H), 7.08 (d, J = 7.8 Hz,
1H), 7.30 (dd, J = 1.0, 7.5 Hz, 1H), 7.39 (m, 1H); 13C NMR (125 MHz,
CDCl3) δ 14.1 (CH3), 22.7 (CH2 × 2), 28.1 (CH2), 29.3 (CH2), 29.4
(CH2), 29.6 (2 × CH2), 29.7 (CH2 × 2), 30.8 (CH), 31.9 (CH2), 55.7
(CH3), 68.1 (CH2), 109.3 (C), 110.5 (C), 111.4 (CH), 115.7 (C), 118.7
(CH), 119.5 (C), 120.7 (CH), 125.3 (CH), 125.5 (C), 128.1 (CH),
128.7 (C), 130.9 (CH), 131.6 (CH), 133.7 (C), 135.1 (C), 141.7 (C),
152.9 (C), 157.2 (C), 180.0 (C), 183.7 (C); EIMS m/z 576 (M+, 35),




[3,4-c]chromene-1,4(7H,12bH)-dione (7d). Following the general
procedure described above, 27.3 mg of embelin (0.09 mmol), 40 mg
(0.14 mmol) of 5-chloro-2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde) and 1.7 mg of EDDA (10 mol %) were suspended in 2
mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C.
The crude was purified by preparative TLC with 30% Hex/EtOAc to
provide 41.6 mg (82%) of 7d as a brown solid. mp 145.6−146.1 °C; IR
(neat) νmax 3335, 2921, 2852, 1645, 1613, 1584, 1480, 1400, 1346, 1328,
1273, 1250, 1220, 1194, 1168, 1117, 1089, 1029, 979, 934, 878, 912
cm−1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 7.0 Hz, 3H), 1.26 (sa,
16H), 1.52 (m, 2H), 2.50 (t, J = 7.7 Hz, 2H), 4.83 (s, 1H), 4.87 (s, 2H),
5.45 (bs, 1H), 6.66 (s, 1H), 6.77 (d, J = 8.6 Hz, 1H), 6.88 (m, 3H), 7.00
(dd, J = 1.5, 8.4 Hz, 1H), 7.25 (m, 1H); 13C NMR (125MHz, CDCl3) δ
14.1 (CH3), 22.7 (2 × CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5
(CH2), 29.6 (CH2), 29.7 (CH2 × 2), 30.9 (CH), 31.9 (CH2), 67.7
(CH2), 108.2 (C), 110.5 (C), 115.3 (CH), 117.2 (CH), 119.0 (CH),
119.7 (C), 120.9 (CH), 125.3 (CH), 126.0 (C), 128.3 (CH), 128.9 (C),
129.8 (CH), 132.5 (C), 144.9 (C), 151.2 (C), 152.1 (C), 152.6 (C),
155.8 (C), 180.1 (C), 183.3 (C); EIMSm/z 562 (M+, 79), 548 (40), 421
(40), 268 (87), 135 (93); HREIMS 564.2114 (calcd. for C33H35O6
37Cl
564.2093), 562.2137 (calcd. for C33H35O6
35Cl 562.2122).
11-Chloro-2-hydroxy-6-phenyl-3-undecylchromeno[3,4-c]-
chromene-1,4(7H,12bH)-dione (7e). Following the general procedure
described above, 25.3 mg (0.09 mmol) of embelin, 35 mg (0.13 mmol)
of 5-chloro-2-((3-(3-phenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.6
mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction
mixture was irradiated for 10 min at 120 °C. The crude was purified by
preparative TLC with 30% Hex/EtOAc to provide 34.6 mg (74%) of 7e
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as a brown solid. mp 146.2−146.7 °C; IR (neat) νmax 3338, 2921, 2851,
1653, 1481, 1401, 1347, 1325, 1249, 1218, 1170, 1116, 1091, 1069,
1020, 1009, 984, 921, 870, 814 cm−1; 1H NMR (500 MHz, CDCl3) δ
0.87 (t, J = 7.0 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t, J = 7.5 Hz,
2H), 4.84 (s, 1H), 4.86 (d, J = 12.9 Hz, 1H), 4.90 (d, J = 12.9 Hz, 1H),
6.66 (d, J = 1.0 Hz, 1H), 6.76 (d, J = 8.6 Hz, 1H), 7.09 (dd, J = 1.1, 8.9
Hz, 1H), 7.42 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 14.1 (CH3),
22.7 (2×CH2), 28.1 (CH2), 29.4 (2×CH2), 29.6 (2×CH2), 29.7 (2×
CH2), 30.9 (CH), 31.9 (CH2), 67.7 (CH2), 107.9 (C), 110.5 (C), 118.9
(CH), 119.7 (C), 125.3 (CH), 126.0 (C), 128.3 (CH), 128.5 (2 ×CH),
128.6 (2 × CH), 128.9 (C), 130.0 (CH), 131.2 (C), 145.3 (C), 151.2
(C), 152.2 (C), 152.6 (C), 179.9 (C), 183.5 (C); EIMS m/z 546 (M+,
91), 518 (35), 405 (43), 294 (37), 252 (100); HREIMS 546.2156 (calcd
for C33H35O5




c]chromene-1,4(7H,12bH)-dione (7f). Following the general proce-
dure described above, 24.8 mg (0.08 mmol) of embelin, 40 mg of 5-
chloro-2-((3-(3-nitrophenyl)prop-2-yn-1-yl)oxy)benzaldehyde (0.13
mmol) and 1.5 mg of EDDA (10 mol %) were suspended in 2 mL of
DCE. The reaction mixture was irradiated for 10 min at 120 °C. The
crude was purified by preparative TLC with 30%Hex/EtOAc to provide
50.8 mg (100%) of 7f as a brown solid. mp 154.1−156.0 °C; IR (neat)
νmax 3523, 3397, 2924, 2853, 1652, 1622, 1532, 1479, 1346, 1256, 1223,
1170, 1113, 1098, 1032, 987, 951, 906, 860, 813 cm−1; 1H NMR (500
MHz, CDCl3) δ 0.87 (t, J = 7.0 Hz, 3H), 1.24 (bs, 16H), 1.50 (m, 2H),
2.50 (t, J = 8.9 Hz, 2H), 4.77 (d, J = 12.9 Hz, 1H), 4.85 (s, 1H), 4.96 (d, J
= 13.3 Hz, 1H), 6.67 (s, 1H), 6.78 (d, J = 8.4 Hz, 1H), 7.10 (d, J = 7.7 Hz,
1H), 7.63 (t, J = 7.6 Hz, 1H), 7.76 (d, J = 7.2 Hz, 1H), 8.23 (s, 1H), 8.28
(d, J = 8.1 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 14.0 (CH3), 22.7
(CH2), 22.8 (CH2), 28.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.6 (2 ×
CH2), 29.7 (2 × CH2), 30.9 (CH), 31.9 (CH2), 67.2 (CH2), 110.4 (C),
110.6 (C), 119.1 (CH), 119.9 (C), 120.0 (C), 123.4 (CH), 124.7 (CH),
125.3 (CH), 126.3 (C), 128.5 (CH), 128.6 (C), 129.8 (CH), 132.9 (C),
134.2 (CH), 142.9 (C), 148.2 (C), 151.8 (C), 152.4 (C), 179.5 (C),
182.5 (C); EIMSm/z 591 (M+, 100), 573 (70), 450 (50), 421 (43), 297
(59); HREIMS 593.1968 (calcd. for C33H34NO7
37Cl, 593.1994),
591.2000 (calcd. for C33H34NO7
35Cl, 591.2024).
11-Chloro-2-hydroxy-6-(3- (t r ifluoromethyl)phenyl )-3-
undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7g). Fol-
lowing the general procedure described above, 23.2 mg of embelin
(0.08 mmol), 40 mg of 5-chloro-2-((3-(3-trifluoromethylphenyl)prop-
2-yn-1-yl)oxy)benzaldehyde (0.12 mmol) and 1.5 mg of EDDA (10mol
%) were suspended in 2mL of DCE. The reactionmixture was irradiated
for 10 min at 120 °C. The crude was purified by preparative TLC with
30% Hex/EtOAc to provide 41.4 mg (86%) of 7g as an amorphous
brown solid. mp 184.3−186.0 °C; IR (neat) νmax 3774, 3534, 3357,
2925, 2854, 1707, 1650, 1619, 1481, 1395, 1336, 1216, 1166, 1066, 810
cm−1; 1H NMR (500 MHz, CDCl3) δ 0.88 (t, J = 7.1 Hz, 3H), 1.26 (bs,
16H), 1.52 (m, 2H), 2.51 (t, J = 7.7 Hz, 2H), 4.79 (d, J = 12.8 Hz, 1H),
4.87 (s, 1H), 4.93 (d, J = 12.8 Hz, 1H), 6.67 (dd, J = 1.0, 2.5 Hz, 1H),
6.79 (d, J = 8.6 Hz, 1H), 7.12 (dd, J = 2.4, 8.7, 1H), 7.59 (m, 2H), 7.65 (s,
1H), 7.70 (dt, J = 2.5, 7.9 Hz, 1H); 13C NMR (125MHz, CDCl3) δ 14.1
(CH3), 22.7 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2),
29.6 (2 × CH2), 29.7 (CH2), 29.8 (CH2), 30.9 (CH), 31.9 (CH2), 67.4
(CH2), 110.5 (C), 110.6 (C), 119.1 (CH), 119.9 (C), 125.2 (CH),
125.3 (CH), 126.3 (C), 126.8 (CH, J C−F = 3.7 Hz), 128.5 (CH), 128.7
(C), 129.3 (CH), 131.1 (C), 131.4 (C), 131.8 (CH), 132.1 (C), 143.9
(C), 151.1 (C), 151.8 (C), 152.4 (C), 179.7 (C), 183.3 (C); EIMS m/z
614 (M+, 86), 596 (76), 444 (38), 320 (67), 173 (87); HREIMS
614.2047 (calcd for C34H34O5




[3,4-c]chromene-1,4(7H,12bH)-dione (7h). Following the general
procedure described above, 23.8 mg (0.09 mmol) of embelin, 40 mg
(0.12 mmol) of 5-bromo-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)-
oxy)benzaldehyde and 1.5 mg of EDDA (10 mol %) were suspended
in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120
°C. The crude was purified by preparative TLCwith 30%Hex/EtOAc to
provide 36.7 mg (73%) of 7h as an amorphous brown solid; mp 140.4−
142.0 °C; IR (neat) νmax 3349, 2922, 2852, 1651, 1619, 1608, 1513,
1476, 1344, 1249, 1219, 1176, 1117, 1088, 1022, 1004, 983, 918, 841,
812 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 7.0 Hz, 3H), 1.26
(bs, 16H), 1.51 (m, 2H), 2.50 (t, J = 7.6 Hz, 2H), 3.83 (s, 3H), 4.82 (s,
1H), 4.86 (d, J = 12.9 Hz, 1H), 4.89 (d, J = 12.9 Hz, 1H), 6.71 (d, J = 8.8
Hz, 1H), 6.78 (d, J = 1.2 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 7.23 (dd, J =
2.1, 8.6 Hz, 1H), 7.33 (d, J = 8.8 Hz, 2H); 13C NMR (125MHz, CDCl3)
δ 14.1 (CH3), 22.7 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4
(CH2), 29.6 (3x CH2), 29.7 (CH2), 30.8 (CH), 31.9 (CH2), 55.4 (CH3),
67.8 (CH2), 106.7 (C), 110.4 (C), 113.2 (C), 113.9 (2 × CH), 119.4
(CH), 119.6 (C), 123.6 (C), 128.1 (CH), 129.5 (C), 129.9 (2 × CH),
131.2 (CH), 145.2 (C), 151.1 (C), 152.2 (C), 153.1 (C), 160.8 (C),
180.0 (C), 183.4 (C); EIMS m/z 622 (M+, 100), 620 (84), 452 (21),
328 (29), 262 (53); HREIMS 622.1757 (calcd for C34H37O6
81Br
622.1753), 620.1788 (calcd for C34H37O6
79Br 620.1774).
11-Bromo-2-hydroxy-6-(3-methoxyphenyl)-3-undecylchromeno-
[3,4-c]chromene-1,4(7H,12bH)-dione (7i). Following the general
procedure described above, 34.2 mg of embelin (0.12 mmol), 60 mg
de 5-bromo-2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benz-
aldehyde (0.17 mmol) and 2.1 mg of EDDA (10 mol %) were
suspended in 2 mL of DCE. The reaction mixture was irradiated for 10
min at 120 °C. The crude was purified by preparative TLC with 30%
Hex/EtOAc to provide 58.3 mg (81%) of 7i as a yellow oil; IR (neat)
νmax 3374, 3055, 2926, 2854, 2361, 2339, 1694, 1646, 1624, 1598, 1477,
1431, 1347, 1263, 1174, 1120, 1082, 1025, 988, 892, 864, 819 cm−1; 1H
NMR (500MHz, CDCl3) δ 0.87 (t, J = 7.1 Hz, 3H), 1.25 (bs, 16H), 1.50
(m, 2H), 2.50 (t, J = 7.4Hz, 2H), 3.82 (s, 3H), 4.82 (s, 1H), 4.88 (s, 2H),
6.70 (d, J = 8.5 Hz, 1H), 6.79 (s, 1H), 6.95 (m, 3H), 7.22 (d, J = 7.8 Hz,
1H), 7.32 (t, J = 7.8 Hz, 1H); 13C NMR (125 MHz, CDCl3)δ 14.1
(CH3), 22.7 (CH2), 22.8 (CH2), 28.2 (CH2), 29.4 (CH2), 29.5 (CH2),
29.6 (CH2), 29.6 (CH2), 29.7 (CH2), 29.7 (CH2), 30.8 (CH), 31.9
(CH2), 55.4 (CH3), 67.7 (CH2), 108.0 (C), 110.4 (C), 113.2 (C), 113.9
(CH), 115.8 (CH), 115.9 (C), 119.4 (CH), 119.7 (C), 120.9 (CH),
128.1 (CH), 129.4 (C), 129.6 (CH), 131.2 (CH), 132.4 (C), 145.2 (C),
152.2 (C), 153.1 (C), 159.6 (C), 179.8 (C), 183.9 (C); EIMS m/z 621
(M+, 32), 620 (16), 481 (6), 382 (16), 135 (100); HREIMS 622.1752
(calcd for C34H37O6




[3,4-c]chromene-1,4(7H,12bH)-dione (7j). 11.4 mg (0.04 mmol) of
embelin, 20 mg (0.06 mmol) of 5-bromo-2-((3-(2-methoxyphenyl)-
prop-2-yn-1-yl)oxy)benzaldehyde and 0.7 mg of EDDA (10% mol)
were dissolved in 2 mL of DCE. The reaction mixture was irradiated at
120 °C for 10 min. The solvent was removed under vacuum and
compound 7j (14.2 mg, 57%) was obtained as an amorphous brown
solid after purification by preparative TLC with 30% Hex/EtOAc as a
yellow oil. IR νmax 3518, 3402, 2924, 2854, 1620, 1477, 1350, 1057, 972,
822, 667 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 6.8 Hz, 3H),
1.25 (bs, 16H), 1.49 (m, 2H), 2.49 (t, J = 7.5 Hz, 2H), 3.79 (s, 3H), 4.47
(d, J = 12.9 Hz, 1H), 4.74 (d, J = 12.9 Hz, 1H), 4.85 (s, 1H), 6.69 (d, J =
8.6 Hz, 1H), 6.80 (dd, J = 1.0, 2.3 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 6.99
(td, J = 0.7, 7.5 Hz, 1H), 7.23 (dd, J = 2.4, 8.8 Hz, 1H), 7.30 (td, J = 1.5,
7.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 14.1 (CH3), 22.7 (CH2 ×
2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.67
(CH2 × 2), 30.7 (CH), 55.7 (CH3), 68.1 (CH2), 109.2 (C), 110.5 (C),
111.4 (CH), 112.8 (C), 119.2 (CH), 119.5 (C), 120.1 (C), 120.8 (CH),
128.2 (CH), 129.2 (C), 130.8 (CH), 131.1 (CH), 131.7 (CH), 151.1
(C), 152.6 (C), 153.4 (C), 157.2 (C), 180.0 (C), 183.5 (C); EIMS m/z
622 (M+, 32), 620 (16), 481 (6), 382 (16), 135 (100); HRMS 622.1752
(calcd. for C34H37O6




[3,4-c]chromene-1,4(7H,12bH)-dione (7k). Twenty-three mg (0.08
mmol) of embelin, 40 mg (0.12 mmol) of 5-bromo-2-((3-(3-
hydroxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.4 mg of
EDDA (10 mol %) were dissolved in 2 mL of DCE. The reaction
mixture was irradiated at 120 °C for 10 min. The solvent was removed
under vacuum and compound 7k (36.6 mg, 75%) was obtained as an
amorphous brown solid after purification by preparative TLC with
Hex:AcOEt 30%. mp 197.2−199.0 °C; IR νmax 3518, 3398, 3255, 3061,
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2951, 2923, 2854, 1620, 1531, 1477, 1350, 1057, 968, 823, 667 cm−1;1H
NMR (500MHz, CDCl3) δ 0.87 (t, J = 7.0 Hz, 3H), 1.26 (bs, 16H), 1.50
(m, 2H), 2.50 (t, J = 7.8 Hz, 2H), 4.84 (s, 1H), 4.87 (d, J = 12.4 Hz, 2H),
4.90 (d, J = 12.4 Hz, 1H), 5.15 (bs, 1H), 6.72 (d, J = 8.6 Hz, 1H), 6.78
(dd, J = 1.0, 2.3 Hz, 1H), 6.90 (m, 1H), 7.24 (d, J = 2.3 Hz, 1H), 7.28 (m.
1H); 13C NMR (125 MHz, CDCl3) δ 14.1 (CH3), 22.7 (CH2), 22.8
(CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2),
29.7 (2 × CH2), 30.8 (CH), 31.9 (CH2), 67.6 (CH2), 108.1 (C), 110.4
(C), 113.3 (C), 115.2 (CH), 117.2 (CH), 119.4 (CH), 119.7 (C), 121.0
(CH), 128.1 (CH), 129.3 (C), 129.8 (CH), 131.3 (CH), 132.5 (C),
144.9 (C), 151.1 (C), 152.1 (C), 153.1 (C), 155.7 (C), 179.9 (C), 183.3
(C); EIMS m/z 608 (M+, 68), 580 (20), 446 (40), 314 (44), 131 (30),
68 (100); HRMS 608.1617 (calcd for C33H35O6
81Br 608.1597),
606.1599 (calcd for C33H35O6
79Br 606.1617).
11-Bromo-2-hydroxy-6-phenyl-3-undecylchromeno[3,4-c]-
chromene-1,4(7H,12bH)-dione (7l). Following the general procedure
described above, 25.0 mg of embelin (0.09 mmol), 40 mg (0.13 mmol)
of 5-bromo-2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde and 1.5 mg of EDDA (10 mol %) were suspended in 2
mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C.
The crude was purified by preparative TLC with 30% Hex/EtOAc to
provide 28.5 mg (57%) of 7l as an amorphous brown solid. mp 146.2−
146.7 °C; IR (neat) νmax 3342, 2920, 2851, 1653, 1619, 1478, 1446,
1398, 1346, 1325, 1249, 1218, 1168, 1117, 1091, 1070, 1008, 983, 920,
861, 811 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.88 (t, J = 7.1 Hz, 3H),
1.26 (bs, 16H), 1.52 (m, 2H), 2.51 (t, J = 7.6 Hz, 2H), 4.85 (s, 1H), 4.87
(d, J = 12.7 Hz, 1H), 4.90 (d, J = 13.0 Hz, 1H), 6.72 (d, J = 8.8 Hz, 1H),
6.80 (s, 1H), 7.24 (d, J = 1.7, 8.5 Hz, 1H), 7.41 (m, 5H); 13C NMR (125
MHz, CDCl3) δ 14.1 (CH3), 22.7 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3
(CH2), 29.4 (CH2), 29.6 (CH2), 29.6 (CH2), 29.7 (CH2), 29.7 (CH2),
30.8 (CH), 31.9 (CH2), 67.7 (CH2), 107.8 (C), 110.5 (C), 113.2 (C),
119.4 (CH), 119.7 (C), 128.1 (CH), 128.4 (CH × 2), 128.6 (CH × 2),
129.4 (C), 130.1 (CH), 131.2 (C), 131.2 (CH), 145.4 (C), 151.1 (C),
152.2 (C), 153.1 (C), 179.9 (C), 183.4 (C); EIMS m/z 592 (M+, 100),
590 (73), 451 (19), 298 (60); HREIMS 592.1650 (calcd for
C33H35O5
81Br 592.1647), 590.1659 (calcd for C33H35O5
79Br 590.1668).
11-Bromo-2-hydroxy-6-(3-nitrophenyl)-3-undecylchromeno[3,4-
c]chromene-1,4(7H,12bH)-dione (7m). Following the general proce-
dure described above, 16.3 mg (0.06 mmol) of embelin, 30 mg (0.08
mmol) of 5-bromo-2-((3-(3-nitrophenyl)prop-2-yn-1-yl)oxy)benz-
aldehyde and 1.0 mg of EDDA (10 mol %) were suspended in 2 mL
of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The
crude was purified by preparative TLC with 30%Hex/EtOAc to provide
31.3 mg (88%) of 7m as a yellow oil. IR (neat) νmax 3383, 3085, 2924,
2853, 2361, 2339, 1697, 1653, 1623, 1533, 1476, 1395, 1345, 1260,
1227, 1173, 1120, 1099, 1029, 989, 952, 908, 853, 815 cm−1; 1H NMR
(500 MHz, CDCl3) δ 0.87 (t, J = 7.1 Hz, 3H), 1.25 (bs, 16H), 1.52 (m,
2H), 2.51 (t, J = 7.6Hz, 2H), 4.79 (d, J = 12.7 Hz, 1H), 4.88 (s, 1H), 4.97
(d, J = 12.7 Hz, 1H), 6.74 (d, J = 8.9 Hz, 1H), 6.80 (d, J = 1.2 Hz, 1H),
7.26 (dd, J = 1.9, 8.6 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.76 (dt, J = 1.6,
7.7 Hz, 1H), 8.23 (t, J = 1.6 Hz, 1H), 8.30 (dd, J = 1.3, 8.3 Hz, 1H); 13C
NMR (125 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1
(CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2),
29.8 (CH2), 30.9 (CH), 31.9 (CH2), 67.2 (CH2), 110.3 (C), 110.6 (C),
113.7 (C), 119.6 (CH), 120.0 (C), 123.4 (CH), 124.8 (CH), 128.2
(CH), 129.0 (C), 129.9 (CH), 131.5 (CH), 132.8 (C), 134.2 (CH),
143.0 (C), 148.2 (C), 151.2 (C), 151.6 (C), 152.9 (C), 179.6 (C), 183.2
(C); EIMS m/z 636 (M+, 96), 635 (94), 618 (67), 501 (32), 343 (37),
149 (100); HREIMS 635.1533 (calcd for C33H34O7
79BrN 635.1519),
636.1481 (calcd for C33H33O7
81BrN 636.1420).
11-Bromo-2-hydroxy-6-(3- ( t r ifluoromethyl )phenyl ) -3-
undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7n). Fol-
lowing the general procedure described above, 30.7 mg (0.1 mmol) of
embelin, 60 mg (0.16 mmol) of 5-bromo-2-((3-(3-trifluoromethyl-
phenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.0 mg of EDDA (10mol
%) were suspended in 2mL of DCE. The reactionmixture was irradiated
for 10 min at 120 °C. The crude was purified by preparative TLC with
30% Hex/EtOAc to provide 64.5 mg (99%) of 7n as an amorphous
brown solid. mp 76.0−77.7 °C; IR (neat) νmax 3368, 2926, 2855, 2360,
2338, 1697, 1649, 1626, 1558, 1477, 1440, 1335, 1263, 1223, 1170,
1129, 1074, 1027, 989, 909, 816 cm−1;1H NMR (500 MHz, CDCl3) δ
0.87 (t, J = 7.1 Hz, 3H), 1.25 (bs, 16H), 1.51 (m, 2H), 2.50 (t, J = 7.3 Hz,
2H), 4.79 (d, J = 12.6 Hz, 1H), 4.86 (s, 1H), 4.93 (d, J = 12.6 Hz, 1H),
6.72 (d, J = 8.5 Hz, 1H), 6.79 (s, 1H), 7.25 (d, J = 8.5 Hz, 1H), 7.58 (m,
2H), 7.64 (s, 1H), 7.70 (d, J = 7.2 Hz, 1H); 13C NMR (500 MHz,
CDCl3) δ 14.1 (CH3), 22.7 (CH2), 22.8 (CH2), 28.2 (CH2), 29.3
(CH2), 29.4 (CH2), 29.6 (CH2), 29.6 (CH2), 29.7 (2 × CH2), 30.8
(CH), 31.9 (CH2), 67.3 (CH2), 109.4 (C), 110.5 (C), 113.5 (C), 119.5
(CH), 119.9 (C), 123.6 (C, JC−F = 272.2 Hz), 125.2 (CH, JC−F = 3.6
Hz), 126.8 (CH, JC−F = 3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH),
131.2 (C, JC−F = 32.4 Hz), 131.4 (CH), 131.7 (CH), 132.0 (C), 143.9
(C), 151.4 (C), 151.9 (C), 152.9 (C), 179.6 (C), 183.6 (C); EIMS m/z
614 (M+, 86), 596 (76), 444 (38), 320 (67), 173 (87); HREIMS
658.1522 (calcd for C34H34O5




chromene-1,4(7H,12bH)-dione (7o). Following the general procedure
described above, 29.4 mg (0.10 mmol) of embelin, 40 mg (0.16 mmol)
of 2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.8
mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction
mixture was irradiated for 10 min at 120 °C. The crude was purified by
preparative TLC with 30% Hex/EtOAc to provide 47.8 mg (88%) of 7o
as an amorphous brown solid. mp 124.7−126.0 °C; IR (neat) νmax 3341,
2924, 2854, 1687, 1650, 1607, 1513, 1485, 1452, 1403, 1355, 1304,
1249, 1223, 1175, 1113, 1085, 1023, 987, 904, 843 cm−1; 1H NMR (500
MHz, CDCl3) δ 0.87 (t, J = 7.2 Hz, 3H), 1.25 (bs, 16H), 1.48 (m, 2H),
2.46 (t, J = 7.5 Hz, 2H), 3.83 (s, 3H), 4.81 (s, 1H), 4.85 (d, J = 12.8 Hz,
1H), 4.91 (d, J = 12.8 Hz, 1H), 6.69 (d, J = 7.2 Hz, 1H), 6.84 (m, 2H),
6.93 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.2 Hz, 2H), 7.12 (t, J = 7.1 Hz, 1H),
7.32 (d, J = 8.2 Hz, 2H); 13C NMR (500 MHz, CDCl3) δ 14.1 (CH3),
22.7 (2 × CH2), 28.2 (CH2), 29.4 (2 × CH2), 29.6 (2 × CH2), 29.7
(CH2× 2), 30.8 (CH), 31.9 (CH2), 55.4 (CH3), 67.7 (CH2), 107.7 (C),
111.0 (C), 113.8 (CH × 2), 117.5 (CH), 119.2 (C), 121.1 (CH), 123.8
(C), 125.2 (CH), 128.2 (C), 128.5 (CH), 128.6 (C), 129.9 (CH × 2),
132.1 (C), 144.5 (C), 153.9 (C), 160.6 (C), 180.1 (C), 183.8 (C); EIMS
m/z 542 (M+, 82), 483 (14), 402 (16), 305 (20), 135 (100); HREIMS
542.2678 (calcd for C34H38O6 (M
+) 542.2668).
2-Hydroxy-6-(3-methoxyphenyl)-3-undecylchromeno[3,4-c]-
chromene-1,4(7H,12bH)-dione (7p). Following the general procedure
described above, 36.8 mg of embelin (0.13 mmol), 50 mg (0.19 mmol)
of 2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.3
mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction
mixture was irradiated for 10 min at 120 °C. The crude was purified by
preparative TLC with 30% Hex/EtOAc to provide 49.4 mg (70%) of 7p
as an amorphous brown solid. mp 69.5−71.2 °C; 1H NMR (500 MHz,
CDCl3) δ 0.88 (t, J = 7.1 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t,
J = 7.7 Hz, 2H), 3.82 (s, 3H), 4.83 (s, 1H), 4.86 (s, 1H), 4.89 (d, J = 13.0
Hz, 1H), 4.92 (d, J = 13.2 Hz, 1H), 6.72 (d, J = 7.7 Hz, 1H), 6.84 (d, J =
8.1 Hz, 1H), 6.88 (t, J = 7.4 Hz, 1H), 6.96 (m, 3H), 7.15 (t, J = 7.6 Hz,
1H), 7.31 (t, J = 7.7 Hz, 1H); IR (neat) νmax 3346, 3057, 2925, 2854,
1693, 1647, 1623, 1602, 1485, 1458, 1348, 1263, 1222, 1179, 1117,
1041, 1024, 990, 866 cm−1; 13CNMR (500MHz, CDCl3) δ 14.1 (CH3),
22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5
(CH2), 29.6 (2 × CH2), 29.7 (CH2), 30.8 (CH), 31.9 (CH2), 55.4
(CH3), 67.6 (CH2), 108.9 (C), 111.0 (C), 113.8 (CH), 115.7 (CH),
117.6 (CH), 119.4 (C), 120.9 (CH), 121.1 (CH), 125.2 (CH), 127.5
(C), 128.2 (CH), 129.5 (CH), 132.6 (C), 144.5 (C), 151.1 (C), 152.0
(C), 153.9 (C), 159.5 (C), 180.1 (C), 183.5 (C); EIMS m/z 542 (M+,




chromene-1,4(7H,12bH)-dione (7q). Following the general procedure
described above, 29.4 mg (0.10 mmol) of embelin, 40 mg (0.15 mmol)
of 2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)-benzaldehyde and 1.8
mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction
mixture was irradiated for 10 min at 120 °C. The crude was purified by
preparative TLC with 30% Hex/EtOAc to provide 43.4 mg (80%) of 7q
as an amorphous brown solid. mp 74.3−75.5 °C; IR (neat) νmax 3308,
3073, 2924, 2853, 1697, 1646, 1620, 1601, 1486, 1460, 1437, 1397,
1348, 1282, 1250, 1223, 1180, 1116, 1082, 1044, 1018, 989, 863, 822
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cm−1; 1H NMR (500 MHz, CDCl3) δ 0.88 (t, J = 7.2 Hz, 3H), 1.26 (bs,
16H), 1.49 (m, 2H), 2.48 (t, J = 8.0 Hz, 2H), 3.80 (s, 3H), 4.49 (d, J =
12.8 Hz, 1H), 4.77 (d, J = 12.8 Hz, 1H), 4.88 (s, 1H), 6.73 (d, J = 7.5 Hz,
1H), 6.82 (d, J = 8.4 Hz, 1H), 6.87 (t, J = 7.5 Hz, 1H), 6.93 (d, J = 8.4 Hz,
1H), 6.99 (t, J = 7.5 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.32 (dd, J = 1.5,
7.7 Hz, 1H), 7.39 (td, J = 1.8, 7.7 Hz, 1H); 13C NMR (500 MHz,
CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3
(CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2 × 3), 30.7 (CH), 31.9
(CH2), 55.6 (CH3), 67.9 (CH2), 110.1 (C), 111.1 (C), 111.3 (CH),
117.4 (CH), 119.2 (C), 120.3 (C), 120.7 (CH), 120.8 (CH), 125.3
(CH), 127.2 (C), 128.1 (CH), 130.9 (CH), 131.5 (CH), 141.2 (C),
151.1 (C), 152.4 (C), 154.2 (C), 157.2 (C), 180.2 (C), 183.6 (C); EIMS
m/z 542 (M+, 82), 483 (14), 402 (16), 305 (20), 135 (100); HREIMS
542.2678 (calcd for C34H38O6 (M
+) 542.2668).
2-Hydroxy-6-(3-hydroxyphenyl)-3-undecylchromeno[3,4-c]-
chromene-1,4(7H,12bH)-dione (7r). Following the general procedure
described above, 30.0 mg (0.08 mmol) of embelin, 30 mg (0.12 mmol)
of 2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.2
mg of EDDA (10mol %) were suspended in 2 mL of DCE. The reaction
mixture was irradiated for 10 min at 120 °C. The crude was purified by
preparative TLC with 30% Hex/EtOAc to provide 38.1 mg (92%) of 7r
as an amorphous brown solid. mp 80.7−81.8 °C; IR (neat) νmax 3365,
2924, 2853, 2360, 2337, 1651, 1621, 1485, 1451, 1351, 1270, 1224,
1202, 1117, 1033, 993 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.88 (t, J =
6.9 Hz, 3H), 1.26 (bs, 16H), 1.50 (m, 2H), 2.49 (t, J = 7.5 Hz, 2H), 4.86
(s, 1H), 4.89 (s, 2H), 6.70 (d, J = 7.4 Hz, 1H), 6.87 (m, 5H), 7.15 (t, J =
7.3 Hz, 1H), 7.23 (m, 1H); 13C NMR (500MHz, CDCl3) δ 14.1 (CH3),
22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.6
(CH2× 3), 29.7 (CH2), 30.8 (CH), 31.9 (CH2), 67.6 (CH2), 109.0 (C),
111.1 (C), 115.3 (CH), 117.1 (CH), 117.6 (CH), 119.4 (CH), 120.8
(C), 121.2 (CH), 125.2 (CH), 127.4 (CH), 128.3 (CH), 129.7 (C),
132.6 (C), 144.3 (C), 151.9 (C), 153.9 (C), 156.0 (C), 180.4 (C), 183.4
(C); EIMSm/z 528 (M+, 62), 447 (37), 388 (18), 277 (100), 235 (52);
HREIMS 528.2515 (calcd for C33H36O6 (M
+) 528.2512).
2-Hydroxy-6-phenyl-3-undecylchromeno[3,4-c]chromene-1,4-
(7H,12bH)-dione (7s). Following the general procedure described
above, 41.5 mg (0.14 mmol) of embelin, 50 mg (0.21 mmol) of 2-((3-
phenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.5 mg of EDDA (10mol
%) were suspended in 2mL of DCE. The reactionmixture was irradiated
for 10 min at 120 °C. The crude was purified by preparative TLC with
30% Hex/EtOAc to provide 53.1 mg (74%) of 7s as an amorphous
brown solid. mp 117.6−119.0 °C; IR (neat) νmax 3344, 3065, 2923,
2852, 2359, 1897, 1654, 1616, 1485, 1450, 1404, 1348, 1326, 1249,
1217, 1180, 1115, 1089, 1071, 1017, 983, 928, 863 cm−1; 1H NMR (500
MHz, CDCl3) δ 0.89 (t, J = 7.1 Hz, 3H), 1.27 (bs, 16H), 1.51 (m, 2H),
2.50 (t, J = 7.8 Hz, 2H), 4.87 (s, 1H), 4.89 (d, J = 12.9 Hz, 1H), 4.93 (d, J
= 12.9 Hz, 1H), 6.72 (d, J = 7.7 Hz, 1H), 6.85 (d, J = 7.9 Hz, 1H), 6.88 (t,
J = 7.4 Hz, 1H), 7.15 (t, J = 7.7 Hz, 1H), 7.41 (m, 5H); 13C NMR (500
MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3
(CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (3 xCH2), 30.8 (CH), 31.9 (CH2),
67.6 (CH2), 108.7 (C), 111.0 (C), 117.5 (CH), 119.4 (C), 121.1 (CH),
125.2 (CH), 127.4 (C), 128.2 (CH), 128.4 (2 × CH), 128.5 (2 × CH),
129.8 (CH), 131.4 (C), 131.8 (C), 144.7 (C), 151.1 (C), 152.0 (C),
153.9 (C), 180.1 (C), 183.5 (C); EIMSm/z 512 (M+, 43), 484 (12), 372
(14), 277 (100), 262 (39); HREIMS 512.2587 (calcd for C33H36O5
(M+) 512.2563).
2-Hydroxy-6-(3-nitrophenyl)-3-undecylchromeno[3,4-c]-
chromene-1,4(7H,12bH)-dione (7t). Following the general procedure
described above, 41.8 mg of embelin (0.14 mmol), 50 mg (0.21 mmol)
of 2-((3-nitrophenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.6 mg of
EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction
mixture was irradiated for 10 min at 120 °C. The crude was purified by
preparative TLC with 30% Hex/EtOAc to provide 62.2 mg (80%) of 7t
as an amorphous brown solid. mp 88.7−89.2 °C; IR (neat) νmax 3387,
2926, 2854, 1653, 1624, 1533, 1484, 1456, 1347, 1262, 1227, 1181,
1117, 1029, 992, 950, 907, 866, 812 cm−1; 1H NMR (500MHz, CDCl3)
δ 0.87 (t, J = 7.1 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t, J = 7.5
Hz, 2H), 4.80 (d, J = 13.1 Hz, 1H), 4.90 (s, 1H), 4.99 (d, J = 13.1 Hz,
1H), 6.72 (d, J = 7.6 Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 6.90 (t, J = 7.4 Hz,
1H), 7.16 (t, J = 7.4Hz, 1H), 7.62 (t, J = 8.2Hz, 1H), 7.77 (dt, J = 1.4, 7.6
Hz, 1H), 8.25 (t, J = 1.7 Hz, 1H), 8.28 (dd, J = 1.4, 8.3 Hz, 1H); 13C
NMR (500 MHz,CDCl3) δ 14.1 (CH3), 22.7 (2 × CH2), 28.1 (CH2),
29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (2 ×CH2), 29.7 (CH2), 30.9
(CH), 31.9 (CH2), 67.1 (CH2), 111.2 (C), 111.3 (C), 117.7 (CH),
119.6 (C), 121.5 (CH), 123.4 (CH), 124.6 (CH), 125.2 (CH), 127.2
(C), 128.5 (CH), 129.7 (CH), 133.0 (C), 134.2 (CH), 142.3 (C), 148.1
(C), 151.2 (C), 151.5 (C), 153.7 (C), 179.8 (C), 183.3 (C); EIMS m/z
557 (M+, 100), 512 (28), 416 (38), 388 (31), 264 (56); HREIMS
557.2440 (calcd for C33H35O7N (M
+) 557.2414).
2-Hydroxy-6-(3-(trifluoromethyl)phenyl)-3-undecylchromeno-
[3,4-c]chromene-1,4(7H,12bH)-dione (7u). Following the general
procedure described above, 32.2 mg (0.11 mmol) of embelin, 50 mg
(0.16 mmol) of 2-((3-(3-trifluoromethylphenyl)prop-2-yn-1-yl)oxy)-
benzaldehyde and 2.6 mg of EDDA (10 mol %) were suspended in 2 mL
of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The
crude was purified by preparative TLC with 30%Hex/EtOAc to provide
51.1 mg (88%) of 7u as a yellow oil. IR (neat) νmax 3347, 3071, 2925,
2854, 2361, 2338, 1695, 1648, 1624, 1485, 1457, 1399, 1335, 1259,
1221, 1169, 1127, 1073, 1027, 992, 909, 865, 810 cm−1; 1H NMR (500
MHz, CDCl3) δ 0.88 (t, J = 7.1 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H),
2.50 (t, J = 7.6 Hz, 2H), 4.80 (d, J = 12.7 Hz, 1H), 4.90 (s, 1H), 4.96 (d, J
= 13.0 Hz, 1H), 6.72 (d, J = 7.7 Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 6.90
(d, J = 7.7 Hz, 1H), 7.17 (t, J = 7.7 Hz, 1H), 7.56 (t, J = 7.8 Hz, 1H), 7.61
(d, J = 7.5 Hz, 1H), 7.66 (s, 1H), 7.69 (d, J = 7.5 Hz, 1H); 13C NMR
(500MHz, CDCl3) δ 14.1 (CH3), 22.7 (CH2), 22.7 (CH2), 28.1 (CH2),
29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6
(CH2), 30.8 (CH), 31.9 (CH2), 67.2 (CH2), 110.3 (C), 111.1 (C),
117.7 (CH), 119.6 (C), 121.4 (CH), 123.7 (C, JC−F = 273.6 Hz), 125.2
(C), 125.2 (CH), 125.3 (CH), 126.6 (CH, JC−F = 3.6 Hz), 127.2 (C),
128.4 (CH), 129.1 (CH), 131.1 (C, JC−F = 33.0 Hz), 131.7 (CH), 132.2
(C), 143.2 (C), 151.1 (C), 151.7 (C), 153.7 (C), 179.9 (C), 183.4 (C);
EIMS m/z 580 (M+, 28), 423 (26), 359 (25), 315 (20), 172 (100);
HREIMS 580.2461 (calcd for C34H35O5F3 (M
+) 580.2437).
2 - H y d r o x y - 1 0 -m e t h o x y - 6 - ( 4 -m e t h o x y p h e n y l ) - 3 -
undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7v). Fol-
lowing the general procedure described above, 26.5 mg (0.09 mmol)
of embelin, 40 mg (0.14 mmol) of 2-((3-(4-methoxyphenyl)- 1511
prop-2-yn-1-yl)oxy)benzaldehyde and 1.6 mg of EDDA (10 mol %)
were suspended in 2mL of DCE. The reactionmixture was irradiated for
10 min at 120 °C. The crude was purified by preparative TLC with 30%
Hex/EtOAc to provide 42.5 mg (82%) of 7v as an amorphous brown
solid. mp 143.1−145.1 °C; IR (neat) νmax 3517, 3398, 3348, 2925. 2853,
1613, 1501, 1464, 1357, 1303, 1061, 972 cm−1; 1H NMR (500 MHz,
CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H), 1.26 (bs, 16H), 1.50 (m, 2H), 2.48 (t,
J = 7.7Hz, 2H), 3.74 (s, 3H), 3.83 (s, 3H), 4.84 (m, 2H), 4.88 (d, J = 12.5
Hz, 1H), 6.39 (d, J = 2.3 Hz, 1H), 6.43 (dd, J = 2.3, 8.6 Hz, 1H), 6.62 (d,
J = 8.6Hz, 1H), 6.93 (d, J = 8.6 Hz, 2H), 7.28 (s, 1H), 7.35 (d, J = 8.8 Hz,
2H); 13C NMR (500 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7
(CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (2 ×
CH2), 29.7 (CH2), 30.4 (CH), 31.9 (CH2), 55.3 (CH3), 55.4 (CH3),
67.6 (CH2), 102.8 (CH), 107.3 (CH), 107.5 (C), 111.5 (C), 113.9 (CH
× 2), 119.3 (C), 119.5 (C), 123.8 (C), 126.0 (CH), 130.0 (CH × 2),
144.8 (C), 151.1 (C), 152.0 (C), 154.8 (C), 159.8 (C), 160.7 (C), 180.2
(C), 183.7 (C); EIMS m/z 572 (M+, 1), 452 (3), 336 (14), 296 (17),
145 (100); HREIMS 572.2747 (calcd for C35H40O7 (M
+) 572.2774).
2 - H y d r o x y - 1 0 -m e t h o x y - 6 - ( 3 -m e t h o x y p h e n y l ) - 3 -
undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7w). Fol-
lowing the general procedure described above, 19.8 mg (0.07 mmol)
of embelin, 30 mg (0.10 mmol) of 2-((3-(3-methoxyphenyl)-prop-2-yn-
1-yl)oxy)benzaldehyde and 1.2 mg of EDDA (10 mol %) were
suspended in 2 mL of DCE. The reaction mixture was irradiated for 10
min at 120 °C. The crude was purified by preparative TLC with 30%
Hex/EtOAc to provide 27.7 mg (72%) of 7w as an amorphous brown
solid. mp 88.2−89.4 °C; IR (neat) νmax 3314, 2924, 2853, 1361, 2338,
1694, 1617, 1500, 1461, 1435, 1347, 1255, 1210, 1160, 1118, 1081,
1029, 930, 838 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 7.1 Hz,
3H), 1.25 (bs, 16H), 1.49 (m, 2H), 2.48 (t, J = 7.6 Hz, 2H), 3.73 (s, 3H),
3.82 (s, 3H), 4.83 (s, 1H), 4.84 (d, J = 12.1 Hz, 1H), 4.90 (d, J = 12.7 Hz,
1H), 6.39 (d, J = 2.5 Hz, 1H), 6.43 (dd, J = 2.4, 8.5 Hz, 1H), 6.62 (d, J =
8.7 Hz, 1H), 6.96 (m, 3H), 7.32 (td, J = 1.4, 7.6 Hz, 1H); 13CNMR (500
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.6b01818
J. Org. Chem. 2016, 81, 9738−9756
9751
MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3
(CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2 × 2), 29.7 (CH2), 30.4
(CH), 31.9 (CH2), 55.3 (CH3), 55.4 (CH3), 67.5 (CH2), 102.8 (CH),
107.3 (CH), 108.7 (C), 111.4 (C), 113.9 (CH), 115.7 (CH), 119.3 (C),
119.4 (C), 121.0 (CH), 126.0 (CH), 129.5 (CH), 132.6 (C), 144.7 (C),
151.1 (C), 151.9 (C), 154.8 (C), 159.6 (C), 159.8 (C), 180.1 (C), 183.6
(C); EIMSm/z 572 (M+, 27), 554 (100), 413 (13), 279 (12), 135 (92);
HREIMS 572.2761 (calcd for C35H40O7 (M
+) 572.2774).
2 - H y d r o x y - 1 0 -m e t h o x y - 6 - ( 2 -m e t h o x y p h e n y l ) - 3 -
undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7x). Follow-
ing the general procedure described above, 24.5 mg (0.08 mmol) of
embelin, 40 mg (0.13 mmol) of 2-((3-(2-methoxyphenyl)-prop-2-yn-1-
yl)oxy)benzaldehyde and 1.5 mg of EDDA (10 mol %) were suspended
in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120
°C. The crude was purified by preparative TLCwith 30%Hex/EtOAc to
provide 23.6 mg (50%) of 7x as a yellow oil. IR (neat) νmax 3312, 2924,
2852, 1706, 1600, 1496, 1460, 1437, 1348, 1281, 1248, 1162, 1116,
1019, 933, 834 cm−1; 1H NMR (500MHz, CDCl3) δ 0.87 (t, J = 7.1 Hz,
3H), 1.25 (bs, 16H), 1.48 (m, 2H), 2.46 (t, J = 6.9 Hz, 2H), 3.73 (s, 3H),
3.80 (s, 3H), 4.47 (d, J = 12.6 Hz, 1H), 4.70 (d, J = 12.6 Hz, 1H), 4.84 (s,
1H), 6.36 (s, 1H), 6.32 (d, J = 2.0 Hz, 1H), 6.63 (d, J = 8.0 Hz, 1H), 6.93
(d, J = 8.3 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 7.33 (dd, J = 1.1, 7.3 Hz,
1H), 7.38 (m, 1H); 13C NMR (500 MHz, CDCl3) δ 14.1 (CH3), 22.6
(CH2), 22.7 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2),
29.6 (2 × CH2), 29.7 (CH2), 30.3 (CH), 31.9 (CH2), 55.3 (CH3), 55.7
(CH3), 67.9 (CH2), 99.7 (C), 102.6 (CH), 106.9 (CH), 109.9 (C),
111.4 (CH), 119.2 (C), 119.3 (C), 120.3 (C), 120.7 (CH), 126.1 (CH),
131.0 (CH), 131.5 (CH), 141.3 (C), 151.1 (C), 152.4 (C), 155.1 (C),
157.2 (C), 159.7 (C), 180.3 (C), 183.7 (C); EIMS m/z 572 (M+, 19),
452 (13), 335 (29), 135 (100); HREIMS 572.2755 (calcd for C35H40O7
(M+) 572.2774).
2 - H y d r o x y - 6 - ( 3 - h y d r o x y p h e n y l ) - 1 0 -m e t h o x y - 3 -
undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7y). Follow-
ing the general procedure described above, 27.8 mg (0.09 mmol) of
embelin, 40 mg (0.14 mmol) of 2-((3-(2-methoxyphenyl)-prop-2-yn-1-
yl)oxy)benzaldehyde and 1.7 mg of EDDA (10 mol %) were suspended
in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120
°C. The crude was purified by preparative TLCwith 30%Hex/EtOAc to
provide 40.0 mg (76%) of 7y as an amorphous brown solid. mp 160.2−
161.4 °C; IR (neat) νmax 3514, 3397, 2923, 2852, 1617, 1500, 1443,
1349, 1154, 1113, 1076, 971 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.88
(t, J = 7.1Hz, 3H), 1.25 (bs, 16H), 1.50 (m, 2H), 2.49 (t, J = 7.7Hz, 2H),
3.74 (s, 3H), 4.82 (m, 2H), 4.89 (d, J = 12.7 Hz, 1H), 5.35 (bs, 1H), 6.39
(s, 1H), 6.44 (dd, J = 1.8, 8.6 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.88 (m,
2H), 6.93 (d, J = 7.5 Hz, 1H), 7.24 (m, 1H); 13C NMR (500 MHz,
CDCl3) δ 14.1 (CH3), 22.7 (2 × CH2), 28.1 (CH2), 29.4 (2 × CH2),
29.6 (3 × CH2), 29.7 (CH2), 30.4 (CH), 31.9 (CH2), 55.4 (CH3), 67.5
(CH2), 102.8 (CH), 107.4 (CH), 108.8 (C), 111.5 (C), 115.4 (CH),
116.5 (C), 110.1 (CH), 119.3 (C), 121.0 (CH), 126.0 (CH), 129.7
(CH), 132.7 (C), 144.5 (C), 151.2 (C), 151.9 (C), 154.8 (C), 155.7
(C), 159.8 (C), 180.3 (C), 183.6 (C); EIMSm/z 558 (M+, 1), 282 (14),




chromene-1,4(7H,12bH)-dione (7z). Following the general procedure
described above, 36.8 mg (0.13 mmol) of embelin, 50 mg (0.19 mmol)
of 2-((3-phenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.3 mg of
EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction
mixture was irradiated for 10 min at 120 °C. The crude was purified by
preparative TLC with 30% Hex/EtOAc to provide 62.4 mg (92%) of 7z
as an amorphous brown solid. mp 151.0−151.8 °C; IR (neat) νmax 3340,
2923, 2853, 2359, 1652, 1615, 1578, 1497, 1444, 1351, 1317, 1253,
1241, 1218, 1157, 1119, 1019, 997, 928, 903, 849 cm−1; 1H NMR (500
MHz, CDCl3) δ 0.87 (t, J = 6.9 Hz, 3H), 1.26 (bs, 16H), 1.50 (m, 2H),
2.49 (t, J = 7.4 Hz, 2H), 3.74 (s, 3H), 4.86 (m, 3H), 6.39 (s, 1H), 6.44 (d,
J = 8.0 Hz, 1H), 6.63 (d, J = 8.2 Hz, 1H), 7.42 (m, 5H); 13C NMR (500
MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7 (CH2), 28.1 (CH2), 29.3
(CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2 × 2), 29.7 (CH2), 30.4
(CH), 31.9 (CH2), 55.4 (CH3), 67.5 (CH2), 102.8 (CH), 107.3 (CH),
108.5 (C), 111.5 (C), 119.3 (C), 119.4 (C), 126.1 (CH), 128.4 (CH ×
2), 128.5 (CH× 2), 129.9 (CH), 131.4 (C), 151.1 (C), 151.9 (C), 154.7
(C), 159.8 (C), 180.2 (C), 183.7 (C); EIMS m/z 542 (M+, 100), 528




[3,4-c]chromene-1,4(7H,12bH)-dione (7aa). Following the general
procedure described above, 22.0 mg of embelin (0.08 mmol), 35 mg
(0.11 mmol) of 2-((3-nitrophenyl)prop-2-yn-1-yl)oxy)-benzaldehyde
and 2.3 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The
reaction mixture was irradiated for 10 min at 120 °C. The crude was
purified by preparative TLC with 30% Hex/EtOAc to provide 27.2 mg
(62%) of 7aa as an amorphous brown solid. mp 93.3−95.0 °C; IR (neat)
νmax 3384, 3055, 2927, 2854, 2360, 1655, 1622, 1534, 1502, 1463, 1441,
1350, 1264, 1227, 1191, 1161, 1121, 1098, 1030, 951, 899, 840, 812
cm−1; 1H NMR (500 MHz, CDCl3) δ 0.87 (t, J = 7.1 Hz, 3H), 1.25 (bs,
16H), 1.50 (m, 2H), 2.49 (t, J = 7.5 Hz, 2H), 3.74 (s, 3H), 4.79 (d, J =
12.5 Hz, 1H), 4.87 (s, 1H), 4.91 (d, J = 13.0 Hz, 1H), 6.41 (d, J = 1.9 Hz,
1H), 6.46 (dd, J = 1.9, 8.3 Hz, 1H), 6.63 (d, J = 8.5 Hz, 1H), 7.63 (t, J =
8.1 Hz, 1H), 7.78 (d, J = 7.7 Hz, 1H), 8.26 (s, 1H), 8.29 (d, J = 8.3 Hz,
1H); 13C NMR (500 MHz, CDCl3) δ 14.1 (CH3), 22.6 (CH2), 22.7
(CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2),
29.7 (2×CH2), 30.5 (CH), 31.9 (CH2), 55.4 (CH3), 67.0 (CH2), 102.9
(CH), 107.8 (CH), 111.0 (C), 111.6 (C), 119.0 (C), 119.6 (C), 123.5
(CH), 124.6 (CH), 126.1 (CH), 129.8 (CH), 133.1 (C), 134.4 (CH),
132.9 (C), 142.5 (C), 148.2 (C), 151.2 (C), 151.4 (C), 154.6 (C), 159.9
(C), 179.8 (C), 183.5 (C); EIMS m/z 587 (M+, 21), 569 (100), 540





lowing the general procedure described above, 17.6 mg (0.06 mmol) of
embelin, 30mg (0.09mmol) of 2-((3-(3-trifluoromethylphenyl)prop-2-
yn-1-yl)oxy)benzaldehyde and 1.1 mg of EDDA (10 mol %) were
suspended in 2 mL of DCE. The reaction mixture was irradiated for 10
min at 120 °C. The crude was purified by preparative TLC with 30%
Hex/EtOAc to provide 14.0 mg (38%) of 7ab as a yellow oil. IR (neat)
νmax 3346, 2925, 2854, 2359, 1651, 1618, 1501, 1461, 1440, 1336, 1248,
1221, 1165, 1074, 1030, 909, 838, 808 cm−1; 1H NMR (500 MHz,
CDCl3) δ 0.87 (t, J = 7.0 Hz, 3H), 1.25 (bs, 16H), 1.50 (m, 2H), 2.49 (t,
J = 7.6Hz, 2H), 3.74 (s, 1H), 4.79 (d, J = 12.5 Hz, 1H), 4.86 (s, 1H), 4.89
(d, J = 12.8 Hz, 1H), 6.41 (d, J = 1.5 Hz, 1H), 6.45 (d, J = 7.7 Hz, 1H),
6.63 (d, J = 8.5, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.62 (d, J = 7.6 Hz, 1H),
7.66 (s, 1H), 7.69 (d, J = 7.6 Hz, 1H); 13C NMR (500 MHz, CDCl3) δ
14.1 (CH3), 22.7 (2 × CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.6
(CH2), 29.6 (CH2), 29.6 (CH2), 29.7 (CH2), 30.5 (CH), 31.9 (CH2),
55.4 (CH3), 67.1 (CH2), 102.8 (CH), 107.6 (CH), 110.1 (C), 111.6
(C), 119.1 (C), 119.5 (C), 123.5 (C, JC−F = 270.8 Hz), 125.4 (CH, JC−F
= 3.8 Hz), 126.1 (CH), 126.6 (CH, JC−F = 3.5 Hz), 129.2 (CH), 131.2
(C, JC−F = 32.3 Hz), 131.9 (CH), 132.2 (C), 143.5 (C), 151.1 (C), 151.6
(C), 154.6 (C), 159.9 (C), 180.0 (C), 183.6 (C); EIMS m/z 610 (M+,





(7ac). Following the general procedure described above, 17.4 mg (0.06
mmol) of embelin, 30 mg (0.10 mmol) of ethyl 4-formyl-3-((3-(4-
methoxyphenyl)prop-2-yn-1-yl)oxy)benzoate) and 1.1 mg of EDDA
(10 mol %) were suspended in 2 mL of DCE. The reaction mixture was
irradiated for 10 min at 120 °C. The crude was purified by preparative
TLC with 30%Hex/EtOAc to provide 21.1 mg (58%) of 7ac as a yellow
oil; IR (neat) νmax 3336, 2929, 2858, 2292, 1634, 1588, 1518, 1463,
1442, 1401, 1332, 1242, 1204, 1145, 1095, 1056, 1019, 994, 899, 863,
833 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.89 (t, J = 7.1 Hz, 3H), 1.27
(bs, 16H), 1.34 (t, J = 7.1Hz, 3H), 1.51 (m, 2H), 2.51 (t, J = 7.7Hz, 2H),
3.74 (s, 3H), 3.84 (s, 3H), 4.31 (q, J = 7.2 Hz, 2H), 4.88 (s, 1H), 4.91 (d,
J = 12.7 Hz, 1H), 4.96 (d, J = 12.4 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 6.94
(d, J = 8.8Hz, 2H), 7.29 (bs, 1H), 7.34 (d, J = 8.8Hz, 2H), 7.44 (t, J = 1.4
Hz, 1H), 7.28 (s, 1H), 7.84 (dd, J = 1.6, 8.4 Hz, 1H); 13C NMR (500
MHz, CDCl3) δ 14.0 (CH3), 14.3 (CH3), 22.7 (CH2), 22.8 (CH2), 28.1
(CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (2 ×
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CH2), 31.0 (CH), 31.9 (CH2), 55.4 (CH3), 60.7 (CH2), 68.1 (CH2),
106.4 (C), 111.0 (C), 114.1 (CH × 2), 117.5 (CH), 119.7 (C), 123.4
(C), 123.7 (C), 126.9 (C), 127.7 (CH), 130.03 (CH × 3), 145.7 (C),
151.3 (C), 152.2 (C), 158.1 (C), 161.1 (C), 166.1 (C), 180.0 (C), 183.6
(C); EIMS m/z 614 (M+, 67), 586 (16), 473 (9), 321 (20), 135 (100);




(7ad). Following the general procedure described above, 17.4 mg (0.06
mmol) of embelin, 30 mg (0.09 mmol) of ethyl 4-formyl-3-((3-(3-
methoxyphenyl)prop-2-yn-1-yl)oxy)benzoate and 1.1 mg of EDDA (10
mol %) were suspended in 2 mL of DCE. The reaction mixture was
irradiated for 10 min at 120 °C. The crude was purified by preparative
TLCwith 30%Hex/EtOAc to provide 23.9 mg (66%) of 7ad as a yellow
oil. IR (neat) νmax 2924, 2854, 1708, 1650, 1609, 1462, 1277, 1249, 1176,
1115, 868, 768, 698 cm−1; 1HNMR (500MHz, CDCl3) δ 0.88 (t, J = 7.1
Hz, 3H), 1.27 (bs, 16H), 1.34 (t, J = 7.1 Hz, 3H), 1.53 (m, 2H), 2.51 (t, J
= 7.5 Hz, 2H), 3.82 (s, 3H), 4.31 (q, J = 7.1 Hz, 2H), 4.87 (s, 1H), 4.91
(d, J = 13.1 Hz, 1H), 4.98 (d, J = 12.7 Hz, 1H), 6.84 (d, J = 8.6 Hz, 1H),
6.97 (m, 3H), 7.32 (t, J = 7.7 Hz, 1H), 7.45 (s, 1H), 7.84 (d, J = 8.4 Hz,
1H); 13C NMR (500 MHz, CDCl3) δ 14.0 (CH3), 14.3 (CH3), 22.7
(CH2), 22.8 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2),
29.6 (CH2), 29.7 (CH2 × 2), 31.0 (CH), 31.9 (CH2), 55.5 (CH3), 60.7
(CH2), 68.0 (CH2), 107.7 (C), 111.0 (C), 114.2 (CH), 116.0 (CH),
117.5 (CH), 119.8 (C), 121.1 (CH), 123.5 (C), 126.9 (C), 127.7 (CH),
129.6 (CH), 130.1 (CH), 132.5 (C), 145.7 (C), 151.3 (C), 152.1 (C),
158.1 (C), 159.9 (C), 166.1 (C), 179.9 (C), 183.6 (C); EIMS m/z 614
(M+, 18), 584 (13), 459 (5), 377 (14), 350 (12), 135 (100); HREIMS




(7ae). Following the general procedure described above, 12.0 mg of
embelin (0.04 mmol), 20 mg (0.06 mmol) of ethyl 4-formyl-3-((3-(2-
methoxyphenyl)prop-2-yn-1-yl)oxy)benzoate and 0.7 mg of EDDA (10
mol %) were suspended in 2 mL of DCE. The reaction mixture was
irradiated for 10 min at 120 °C. The crude was purified by preparative
TLC with 30%Hex/EtOAc to provide 16.0 mg (67%) of 7ae as a yellow
oil. IR (neat) νmax 2924, 2854, 1708, 1639, 1609, 1462, 1350, 1277, 1246,
1176, 1115, 1018, 841, 756, 659 cm−1; 1H NMR (500 MHz, CDCl3) δ
0.89 (t, J = 7.0 Hz, 3H), 1.27 (bs, 16H), 1.34 (t, J = 7.1 Hz, 3H), 1.52 (m,
2H), 2.50 (t, J = 7.6 Hz, 2H), 3.79 (s, 3H), 4.31 (q, J = 7.2 Hz, 2H), 4.56
(d, J = 12.3 Hz, 1H), 4.78 (d, J = 12.3 Hz, 1H), 4.89 (s, 1H), 6.82 (d, J =
8.7 Hz, 1H), 6.95 (d, J = 8.7 Hz, 1H), 6.99 (t, J = 7.6 Hz, 1H), 7.30 (dd, J
= 1.5, 7.6 Hz, 1H), 7.39 (m, 1H), 7.46 (s, 1H), 7.83 (dd, J = 1.5, 8.6 Hz,
1H); 13C NMR (500 MHz, CDCl3) δ 14.0 (CH3), 14.3 (CH3), 22.7
(CH2), 22.8 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.6 (CH2),
29.7 (CH2 × 3), 30.9 (CH), 31.9 (CH2), 55.9 (CH3), 60.7 (CH2), 68.5
(CH2), 109.0 (C), 111.0 (C), 111.8 (CH), 117.3 (CH), 119.6 (C),
120.5 (C), 120.9 (CH), 123.2 (C), 126.8 (C), 127.8 (CH), 130.0 (CH),
131.0 (CH), 131.7 (CH), 142.3 (C), 151.3 (C), 152.6 (C), 157.5 (C),
158.4 (C), 166.2 (C), 180.0 (C), 183.8 (C); EIMS m/z 614 (M+, 20),





(7af). Following the general procedure described above, 12.1 mg (0.04
mmol) of embelin, 20 mg (0.06 mmol) of ethyl 4-formyl-3-((3-(3-
hydroxyphenyl)prop-2-yn-1-yl)oxy)benzoate and 0.8 mg of EDDA (10
mol %) were suspended in 2 mL of DCE. The reaction mixture was
irradiated for 10 min at 120 °C. The crude was purified by preparative
TLC with 30% Hex/EtOAc to provide 13.8 mg (56%) of 7af as a yellow
oil; IR (neat) νmax 3391, 2920, 2854, 1693, 1655, 1624, 1492, 1393,
1354, 1258, 1176, 1115, 960, 872, 825, 764, 660 cm−1; 1H NMR (500
MHz, CDCl3) δ 0.87 (t, J = 7.0 Hz, 3H), 1.25 (bs, 16H), 1.34 (t, J = 7.0
Hz, 3H), 1.50 (m, 2H), 2.49 (t, J = 8.0 Hz, 2H), 4.32 (q, J = 7.2 Hz, 2H),
4.87 (s, 1H), 4.89 (d, J = 12.8 Hz, 1H), 4.97 (d, J = 12.8 Hz, 1H), 6.83 (d,
J = 8.5 Hz, 1H), 6.88 (m, 3H), 7.24 (m, 1H), 7.42 (t, J = 1.2 Hz, 1H),
7.83 (dd, J = 1.7, 8.5 Hz, 1H); 13C NMR (500 MHz, CDCl3) δ 14.1
(CH3), 14.3 (CH3), 22.7 (2 × CH2), 28.1 (CH2), 29.3 (CH2), 29.4
(CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (2 × CH2), 30.8 (CH), 31.9
(CH2), 60.9 (CH2), 67.5 (CH2), 107.4 (C), 110.8 (C), 115.3 (CH),
117.3 (CH), 117.5 (CH), 119.6 (CH), 120.8 (C), 123.1 (C), 126.6 (C),
127.6 (CH), 129.8 (CH), 130.1 (CH), 132.3 (C), 145.3 (C), 151.4 (C),
151.9 (C), 155.9 (C), 157.9 (C), 166.3 (C), 180.2 (C), 183.4 (C); EIMS
m/z 558 (M+, 1), 282 (14), 254 (18), 131 (100); HREIMS 558.2609




ing the general procedure described above, 19.1 mg (0.04 mmol) of
embelin, 30 mg (0.10 mmol) of ethyl 4-formyl-3-((3-(3-phenyl)prop-2-
yn-1-yl)oxy)benzoate and 1.2 mg of EDDA (10 mol %) were suspended
in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120
°C. The crude was purified by preparative TLCwith 30%Hex/EtOAc to
provide 30.3 mg (80%) of 7ag as an oil. IR (neat) νmax 2924, 2845, 1709,
1655, 1620, 1450, 1350, 1288, 2346, 1177, 1115, 1018, 983, 841, 767,
698 cm−1; 1H NMR (500 MHz, CDCl3) δ 0.89 (t, J = 7.1 Hz, 3H), 1.28
(bs, 16H), 1.35 (t, J = 7.1Hz, 3H), 1.54 (m, 2H), 2.52 (t, J = 7.8Hz, 2H),
4.31 (q, J = 7.0Hz, 2H), 4.90 (s, 1H), 4.92 (d, J = 13.2 Hz, 1H), 4.96 (d, J
= 12.4 Hz, 1H), 6.84 (d, J = 8.5 Hz, 1H), 7.42 (m, 6H), 7.84 (dd, J = 1.5,
8.5 Hz, 1H); 13C NMR (500 MHz, CDCl3) δ 14.0 (CH3), 14.3 (CH3),
22.7 (CH2), 22.8 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.6 (2×
CH2), 29.7 (2×CH2), 30.0 (CH), 31.9 (CH2), 60.7 (CH2), 68.0 (CH2),
107.5 (C), 111.0 (C), 117.5 (CH), 119.8 (C), 123.5 (C), 126.8 (C),
127.7 (CH), 128.6 (CH × 4), 130.1 (CH × 2), 131.4 (C), 145.9 (C),
151.3 (C), 152.2 (C), 158.0 (C), 166.1 (C), 179.9 (C), 183.6 (C); EIMS
m/z 584 (M+, 86), 540 (28), 443 (19), 291 (45), 105 (100); HREIMS




(7ah). Following the general procedure described above, 16.6 mg (0.04
mmol) of embelin, 30 mg (0.085 mmol) of ethyl 4-formyl-3-((3-(3-
nitrophenyl)prop-2-yn-1-yl)oxy)benzoate and 1.1 mg of EDDA (10
mol %) were suspended in 2 mL of DCE. The reaction mixture was
irradiated for 10 min at 120 °C. The crude was purified by preparative
TLC with 30% Hex/EtOAc to provide 28.8 mg (82%) of 7ah as an oil;
IR (neat) νmax 3379, 2924, 2854, 1709, 1654, 1623, 1531, 1477, 1389,
1288, 1245, 1177, 1119, 1026, 984, 856, 787, 768, 690 cm−1; 1H NMR
(500MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H), 1.27 (bs, 16H), 1.35 (t, J =
7.1 Hz, 3H), 1.54 (m, 2H), 2.53 (t, J = 7.8 Hz, 2H), 4.32 (q, J = 7.2 Hz,
2H), 8.87 (d, J = 12.8 Hz, 1H), 4.94 (s, 1H), 4.99 (d, J = 12.8 Hz, 1H),
8.87 (d, J = 8.6 Hz, 1H), 7.46 (t, J = 1.5 Hz, 1H), 7.64 (t, J = 8.2 Hz, 1H),
7.77 (d, J = 7.8 Hz, 1H), 7.86 (dd, J = 1.7, 8.5 Hz, 1H), 8.25 (t, J = 1.7 Hz,
1H), 8.30 (d, J = 8.4 Hz, 1H); 13C NMR (500 MHz, CDCl3) δ 14.0
(CH3), 14.3 (CH3), 22.7 (CH2), 22.8 (CH2), 28.1 (CH2), 29.3 (CH2),
29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (2 × CH2), 31.1 (CH), 31.9
(CH2), 60.8 (CH2), 67.5 (CH2), 109.9 (C), 111.1 (C), 117.6 (CH),
120.1 (C), 123.6 (CH), 123.9 (C), 124.8 (CH), 126.5 (C), 127.7 (CH),
129.9 (CH), 130.3 (CH), 133.0 (C), 134.3 (CH), 143.5 (C), 148.5 (C),
151.3 (C), 151.6 (C), 157.7 (C), 166.0 (C), 179.6 (C), 183.4 (C); EIMS
m/z 587 (M+, 21), 569 (100), 540 (20), 452 (16), 294 (17), 166 (51);




ylate (7ai). Following the general procedure described above, 20.8 mg
(0.07 mmol) of embelin, 40 mg (0.11 mmol) of ethyl 4-formyl-3-((3-(3-
trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzoate and 1.3 mg of
EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction
mixture was irradiated for 10 min at 120 °C. The crude was purified by
preparative TLCwith 30%Hex/EtOAc to provide 28.8 mg (82%) of 7ai
as an oil. IR (neat) νmax 2928, 2854, 1709, 1639, 1616, 1477, 1335, 1288,
1246, 1169, 1123, 1072, 1026, 987, 910, 845, 810, 767, 698 cm−1; 1H
NMR (500 MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H), 1.35 (t, J = 7.1 Hz,
3H), 1.27 (bs, 16H), 1.54 (m, 2H), 2.52 (t, J = 7.8 Hz, 2H), 4.32 (q, J =
7.1 Hz, 2H), 4.87 (d, J = 12.7 Hz, 1H), 4.92 (s, 1H), 4.96 (d, J = 13.0 Hz,
1H), 6.86 (d, J = 8.6 Hz, 1H), 7.46 (s, 1H), 7.58 (t, J = 7.7 Hz, 1H), 7.62
(d, J = 7.8, 1H), 7.66 (s, 1H), 7.71 (d, J = 7.5 Hz, 1H), 7.85 (dd, J = 1.4,
8.6 Hz, 1H); 13C NMR (500 MHz, CDCl3) δ 14.0 (CH3), 14.3 (CH3),
22.7 (CH2), 22.8 (CH2), 28.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.6
(CH2), 29.6 (CH2), 29.7 (CH2 × 2), 31.0 (CH), 31.9 (CH2), 60.8
(CH2), 67.6 (CH2), 109.1 (C), 111.1 (C), 117.6 (CH), 119.6 (C), 123.7
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(C, JC−F= 269.7 Hz), 123.8 (C), 125.5 (CH, JC−F = 3.6 Hz), 126.6 (C),
126.6 (C), 126.9 (CH, JC−F = 3.0 Hz), 127.8 (CH), 129.3 (CH), 130.2
(CH), 131.9 (CH), 132.2 (C), 144.4 (C), 151.4 (C), 151.8 (C), 157.8
(C), 166.0 (C), 179.7 (C), 183.5 (C); EIMS m/z 652 (M+, 63), 608
(43), 512 (21), 415 (30), 360 (38), 173 (100); HREIMS 652.2616
(calcd for C37H39O7F3 (M
+) 652.2648).
11-Chloro-6-(4-methoxyphenyl)-3,4,7,12b-tetrahydrochromeno-
[3,4-c]chromen-1(2H)-one (14). 7.5 mg (0.07 mmol) of 1,3-cyclo-
hexanedione, 30 mg (0.1 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)-
benzaldehyde and 1.2 mg of EDDA (10 mol %) were dissolved in 2 mL
of DCE. The reaction mixture was irradiated at 120 °C for 10 min. The
solvent was removed under vacuum and compound 14 (23.2 mg, 87%)
was obtained as an amorphous withe solid after purification by
preparative TLC with 30% Hex/EtOAc. mp 109.4−110.6 °C; 1H NMR
(500 MHz, CDCl3) δ 2.15 (m, 2H), 2.58 (m, 2H), 2.62 (m, 1H), 2.74
(m, 1H), 3.83 (s, 3H), 4.66 (s, 1H), 4.81 (d, J = 12.2Hz, 1H), 4.84 (d, J =
12.4 Hz, 1H), 6.69 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 1.2, 2.6 Hz, 1H),
6.93 (d, J = 8.8 Hz, 1H), 7.04 (ddd, J = 0.8, 2.6, 8.6 Hz, 1H), 7.28 (d, J =
8.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 20.0 (CH2), 27.9 (CH2),
30.2 (CH), 36.9 (CH2), 55.4 (CH3), 67.9 (CH2), 107.5 (C), 109.8 (C),
113.8 (2 × CH), 118.3 (CH), 124.4 (C), 125.5 (C), 125.7 (CH), 127.5
(CH), 129.8 (2 × CH), 130.2 (C), 144.6 (C), 152.6 (C), 160.5 (C),
168.7 (C), 198.3 (C); EIMS m/z 394 (M+, 10), 393 (11), 362 (6), 274
(11), 135 (100); HREIMS 394.0978 (calcd. for C23H19O4
35Cl
394.0972), 396.0926 (calcd. for C23H19O4
37Cl 396.0942).
11-Chloro-6-(4-methoxyphenyl)-3,3-dimethyl-3,4,7,12b-
tetrahydrochromeno[3,4-c]chromen-1(2H)-one (15). Ten mg (0.07
mmol) of dimedone, 20 mg (0.1 mmol) of 5-chloro-2-(prop-2-yn-1-
yloxy)benzaldehyde and 1.2 mg of EDDA (10 mol % mol) were
dissolved in 2mL of DCE. The reaction mixture was irradiated at 120 °C
for 10 min. The solvent was removed under vacuum and compound 15
(28.6 mg, 94%) was obtained as an amorphous withe solid after
purification by preparative TLCwith 30% n-hexanes:AcOEt. mp 116.0−
117.4 °C; IR (neat) νmax 2959, 1678, 1601, 1512, 1477, 1373, 1254,
1169, 1026, 910, 787, 729, 648 cm−1; 1H NMR (500 MHz, CDCl3) δ
1.17 (s, 1H), 1.24 (s, 1H), 2.42 (m, 2H), 2.49 (m, 1H), 2.56 (m, 1H),
3.83 (s, 3H), 4.66 (s, 1H), 4.81 (d, J = 12.2 Hz, 1H), 4.84 (d, J = 12.4 Hz,
1H), 6.69 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 1.2, 2.6 Hz, 1H), 6.92 (d, J =
8.8 Hz, 1H), 7.03 (dd, J = 2.5, 8.7 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H); 13C
NMR (125 MHz, CDCl3) δ 27.7 (CH3), 29.3 (CH3), 30.3 (CH), 41.5
(CH2), 50.9 (CH2), 55.4 (CH3), 67.9 (CH2), 107.3 (C), 108.7 (C),
113.8 (2 × CH), 118.3 (CH), 124.4 (C), 125.5 (C), 125.8 (CH), 127.5
(CH), 129.7 (CH × 2), 130.6 (C), 144.7 (C), 152.4 (C), 160.4 (C),
166.9 (C), 198.3 (C); EIMS m/z 424 (M+, 48), 421 (100), 391 (62),
338 (18), 295 (19), 135 (44); HREIMS 424.1271 (calcd. for
C25H23O4




[4′,3′:4,5]pyrano[2,3-d]pyrimidine-1,3(2H,4H)-dione (16). 5.6 mg
(0.044 mmol) of barbituric acid, 20 mg (0.07 mmol) of 5-chloro-2-
(prop-2-yn-1-yloxy)benzaldehyde and 0.8 mg of EDDA (10% mol)
were dissolved in 2 mL of DCE. The reaction mixture was irradiated at
120 °C for 10 min. The solvent was removed by filtration and washed
with n-hexane. Compound 16 (19.1 mg, 89%) was obtained as a withe
solid. mp 275.2−277.0 °C; IR (neat) νmax 3233, 3113, 2912, 2824, 1690,
1582, 1474, 1373, 1350, 1285, 1027, 1049, 852, 764, 675 cm−1; 1HNMR
(500MHz, CDCl3) δ 3.80 (s, 3H), 4.66 (m, 2H), 4.99 (bs, 1H), 5.02 (d,
J = 12.2Hz, 1H), 6.80 (d, J = 8.6Hz, 1H), 7.05 (m, 3H), 7.16 (dd, J = 2.0,
8.3 Hz, 1H), 7.36 (d, J = 8.7 Hz, 1H); 13C NMR (150 MHz, CDCl3) δ
30.9 (CH), 55.8 (CH3), 67.6 (CH2), 84.3 (C), 107.5 (C), 114.4 (CH ×
2), 118.8 (CH), 123.5 (C), 124.6 (C), 126.6 (CH), 128.0 (CH), 130.2
(CH × 2), 143.9 (C), 150.1 (C), 152.8 (C), 155.9 (C), 160.8 (C), 165.3
(C), 172.5 (C); EIMSm/z 652 (M+, 63), 608 (43), 512 (21), 415 (30),




pyrano[3′,2′:5,6]pyrano[3,4-c]chromen-1-one (17a) and 11-Chloro-
6-(4-methoxyphenyl)-3-methyl-7,12b-dihydro-1H-pyrano[3′,4′:5,6]-
pyrano[3,4-c]chromen-1-one (17b). Twelve mg (0.07 mmol) of 2-
methy-4-hydroxypirone, 30 mg (0.1 mmol) of 5-chloro-2-(prop-2-yn-1-
yloxy)benzaldehyde and 1.2 mg of EDDA (10 mol %) were dissolved in
2mL of DCE. The reactionmixture was irradiated in a sealed tube at 120
°C for 10 min. The solvent was removed under vacuum and compound
17a (19.1 mg, 45%) and 17b (20.5 mg, 45%) were obtained as withe
solids after purification by preparative TLC with 40% Hex/EtOAc.
17a: mp 230.1−232.1 °C; IR (neat) νmax 3522, 3402, 1693, 1666,
1601, 1477, 1427, 1246, 1169, 1076, 957, 833, 663 cm−1; 1H NMR (500
MHz, CDCl3) δ 2.31 (s, 1H), 3.84 (s, 3H), 4.83 (d, J = 12.4 Hz, 1H),
4.87 (d, J = 12.4 Hz, 1H), 4.94 (s, 1H), 6.23 (s, 1H), 6.72 (d, J = 8.7 Hz,
1H), 6.94 (d, J = 8.5 Hz, 2H), 6.97 (s, 1H), 7.07 (d, J = 8.5 Hz, 1H), 7.32
(d, J = 8.4 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 19.2 (CH3), 32.1
(CH), 55.4 (CH3), 67.5 (CH2), 97.3 (C), 107.9 (C), 113.7 (CH), 113.9
(CH × 2), 118.3 (CH), 123.3 (C), 125.9 (C), 126.2 (CH), 128.0 (CH),
129.1 (C), 129.9 (CH × 2), 144.3 (C), 152.4 (C), 160.8 (C), 161.3 (C),
161.7 (C), 179.9 (C); EIMS m/z 408 (M+, 100), 392 (25), 376 (22),
322 (23), 294 (24); HREIMS: 408.0776 (calcd. for C23H17O5
35Cl
408.0765), 410.0754 (calcd. for C23H17O5
37Cl 410.0754).
17b: mp 260.4−261.4 °C; IR (neat) νmax 3525, 3402, 2839, 1709,
1651, 1589, 1512, 1416, 1300, 1288, 1250, 1238, 1034, 968, 930, 818,
663 cm−1; 1H NMR (500 MHz, CDCl3) δ 2.31 (s, 1H), 3.84 (s, 3H),
4.75 (s, 1H), 4.82 (d, J = 12.4 Hz, 1H), 4.86 (d, J = 12.4 Hz, 1H), 5.92 (s,
1H), 6.73 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.8 Hz, 2H), 7.07 (m, 2H),
7.29 (d, J = 8.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 20.0 (CH3),
31.1 (CH), 55.4 (CH3), 67.8 (CH2), 96.3 (C), 99.1 (CH), 107.0 (C),
113.9 (CH × 2), 118.4 (CH), 124.0 (C), 125.6 (CH), 125.9 (C), 127.9
(CH), 129.4 (C), 129.8 (CH × 2), 144.5 (C), 152.5 (C), 160.7 (C),
162.2 (C), 162.6 (C), 164.6 (C); EIMS m/z 408 (M+, 100), 392 (20),
376 (19), 322 (15), 294 (18); HREIMS: 408.0777 (calcd. for
C23H17O5




dichromen-14(14bH)-one (18a) and 5-Chloro-14-(4-methoxyphen-
yl)-1H-pyrano[3,2-c:5,4-c′]dichromen-7(6bH)-one (18b). Fourteen
mg (0.07 mmol) of 4-hydroxycumarin, 30 mg (0.1 mmol) of 5-
chloro-2-(prop-2-yn-1-yloxy)benzaldehyde and 1.2 mg of EDDA (10
mol %) were dissolved in 2 mL of DCE. The reaction mixture was
irradiated at 120 °C for 10 min. The solvent was removed under vacuum
and compound 18a (13.6 mg, 37%) and 18b (21.6 mg, 56%) were
obtained as white solids after purification by preparative TLC with 1%
toluene/acetone.
18a: mp 290.6−292.1 °C; IR (neat) νmax 1709, 1612, 1570, 1477,
1423, 1242, 1053, 987, 975, 813, 756, 713, 682 cm−1; 1H NMR (500
MHz, CDCl3) δ 3.86 (s, 3H), 4.88 (d, J = 12.4 Hz, 1H), 4.95 (d, J = 12.4
Hz, 1H), 5.10 (s, 1H), 6.75 (d, J = 8.4 Hz, 1H), 6.95 (s, 1H), 6.97 (d, J =
8.8 Hz, 2H), 7.07 (dd, J = 1.2, 8.4 Hz, 1H), 7.37 (d, J = 8.9 Hz, 2H), 7.47
(m, 2H), 7.71 (t, J = 7.3 Hz, 1H), 8.32 (d, J = 7.4, 1H); 13C NMR (125
MHz, CDCl3) δ 32.5 (CH), 55.4 (CH3), 67.5 (CH2), 94.7 (C), 108.3
(C), 114.0 (2 × CH), 117.4 (CH), 118.3 (CH), 123.2 (C), 123.3 (C),
125.7 (CH), 125.9 (C), 126.1 (CH), 126.3 (CH), 128.0 (CH), 129.4
(C), 129.9 (CH × 2), 133.8 (CH), 144.2 (C), 152.4 (C), 153.1 (C),
160.9 (C), 161.6 (C), 178.1 (C); EIMSm/z 444 ([M+], 100), 429 (30),
413 (43), 324 (21), 295 (2); HREIMS 446.0766 (calcd. for
C26H17O5
37Cl (M+) 446.0735), 444.0753 (calcd. for C26H17O5
35Cl
(M+) 444.0765).
18b: mp 293.8−295.1 °C; IR (neat) νmax 1712, 1608, 1512, 1477,
1377, 1288, 1049, 995, 941, 814, 652 cm−1; 1H NMR (500 MHz,
CDCl3) δ 3.87 (s, 3H), 4.89 (d, J = 12.1 Hz, 1H), 4.90 (s, 1H), 4.95 (d, J
= 12.5 Hz, 1H), 6.76 (d, J = 8.6 Hz, 1H), 6.99 (d, J = 8.6Hz, 2H), 7.04 (s,
1H), 7.08 (dd, J = 1.7, 8.6 Hz, 1H), 7.32 (t, J = 7.7 Hz, 1H), 7.41 (d, J =
8.7 Hz, 2H), 7.44 (d, J = 8.2Hz, 1H), 7.62 (t, J = 7.7, 1H), 7.81 (d, J = 7.9
Hz, 1H), 7.81 (d, J = 7.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 31.7
(CH), 55.4 (CH3), 67.9 (CH2), 98.8 (C), 107.1 (C), 109.8 (C), 114.0
(CH × 2), 116.9 (CH), 118.6 (CH), 123.0 (CH), 124.0 (C), 124.4
(CH), 125.4 (CH), 126.0 (C), 128.0 (CH), 129.3 (C), 129.8 (2 ×CH),
132.7 (CH), 144.4 (C), 152.5 (C), 153.0 (C), 157.7 (C), 160.8 (C),
162.8 (C); EIMSm/z 444 (M+, 100), 429 (28), 413 (41), 324 (20), 295





chromene-9,14(6H,14bH)-dione (19a) and 5-Chloro-14-(4-
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methoxyphenyl)benzo[h]chromeno[3,4-c]chromene-7,8(1H,6bH)-
dione (19b). 7.72 mg (0.044 mmol) of 2-hydroxy-1,4-naphtoquinone,
20 mg (0.07 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde
and 1 mg of EDDA (10 mol %) were dissolved in 2 mL of DCE. The
reaction mixture was irradiated at 120 °C for 10 min. The solvent was
removed under vacuum and compound 19a (11.1 mg, 55%) and 19b
(6.1 mg, 31%) were obtained as white solids after purification by
preparative TLC with 1% DCM/MeOH.
19a: mp 164.2−165.8 °C; IR νmax 1680, 1642, 1548, 1258, 1352,
1172, 1076, 1022, 965, 825, 725 cm−1; 1H NMR (500 MHz, CDCl3) δ
3.84 (s, 1H), 4.90 (d, J = 12.4 Hz, 1H), 4.95 (d, J = 12.8 Hz, 1H), 5.02 (s,
1H), 6.66 (d, J = 1.4 Hz, 1H), 6.77 (d, J = 8.6 Hz, 1H), 6.95 (d, J = 8.8
Hz, 2H), 7.08 (dd, J = 2.3, 8.7 Hz, 1H), 7.38 (d, J = 8.6 Hz, 2H), 7.79 (td,
J = 1.2, 7.7 Hz, 1H), 7.83 (td, J = 1.0, 7.4 Hz, 1H), 8.18 (d, J = 7.7 Hz,
1H), 8.24 (d, J = 7.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 31.3
(CH), 55.4 (CH3), 67.9 (CH2), 106.5 (C), 113.9 (2 × CH), 117.4 (C),
118.8 (CH), 123.8 (C), 125.3 (CH), 125.8 (C), 126.7 (CH × 2), 128.0
(CH), 129.5 (C), 129.9 (2 × CH), 130.8 (C), 131.6 (C), 133.9 (CH),
134.6 (CH), 144.9 (C), 152.5 (C), 152.6 (C), 160.7 (C), 177.9 (C),
184.8 (C); EIMSm/z 456 (M+, 100), 384 (19), 282 (40), 252 (30), 135




19b: 122.8−124.0 °C; IR νmax 1674, 1605, 1512, 1477, 1300, 1250,
1177, 1076, 1026, 983, 818, 717, 671 cm−1; 1H NMR (500 MHz,
CDCl3) δ 3.87 (s, 1H), 4.90 (d, J = 12.6 Hz, 1H), 4.92 (s, 1H), 4.95 (d, J
= 12.4 Hz, 1H), 6.72 (d, J = 1.8 Hz, 1H), 6.75 (d, J = 8.6 Hz, 1H), 7.00
(d, J = 8.5 Hz, 2H), 7.07 (dd, J = 2.3, 8.7 Hz, 1H), 7.40 (d, J = 8.8 Hz,
2H), 7.64 (t, J = 7.4 Hz, 1H), 7.71 (t, J = 7.7 Hz, 1H), 7.87 (d, J = 7.8 Hz,
1H), 8.23 (d, J = 7.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 30.9
(CH), 55.5 (CH3), 67.6 (CH2), 108.2 (C), 110.8 (C), 113.6 (C), 114.6
(CH × 2), 118.6 (CH), 123.8 (C), 124.9 (CH), 125.6 (CH), 126.0 (C),
128.1 (CH), 129.6 (CH), 129.8 (CH × 2), 131.1 (C), 131.9 (CH),
133.3 (C), 135.3 (CH), 144.4 (C), 152.6 (C), 160.2 (C), 160.8 (C),
178.2 (C), 179.8 (C); EIMS m/z 456 (M+, 9), 437 (35), 334 (11), 152
(43), 135 (100); HREIMS 458.0750 (calcd. for C27H17O5
37Cl
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1H and 13C NMR spectra of compounds 6a−6ai and 7a−
7ai; HMBC spectrum of compound 7a (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*Tel.: 34 922318576. Fax: 34 922 318571. E-mail: aestebra@ull.
es.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
We gratefully acknowledge the financial support from the
Spanish MINECO SAF 2015-65113-C2-1-R to A.E.B. This
project is also cofunded by the European Regional Development
Fund (FEDER). G.F. and A.T. are grateful to CICITCA-UNSJ
and CONICET, Argentina. P.M.A. thanks ACIISI for a
predoctoral grant.
■ REFERENCES
(1) Harvey, A. L. Drug Discovery Today 2008, 13, 894−900.
(2) Patridge, E.; Gareiss, P.; Kinch, M. S.; Hoyer, D. Drug Discovery
Today 2016, 21, 204−207.
(3) (a) Thomson, S. D. Naturally Occurring Quinones IV: Recent
Advances; Chapman &Hall, Thomson Press: India, 1997. (b) Ravelo, A.
G.; Estev́ez-Braun, A.; Chav́ez-Orellana, H.; Peŕez-Sacau, E.; Mesa-
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